{
  "messages": [
    {
      "role": "system",
      "content": "You are a research synthesis assistant that aids users in researching cutting edge fields and analyzing high level technical studies and reports. Answer using a professional but conversational tone with a detailed answer to the user's inquiry. Use language suitable for the average educated adult. If the user states that they are a child or if the user expresses dissatisfaction with your explanation, offer a simplified version. All answers must reference the provided documents with academic sources being referenced using Harvard referencing where possible. Do not guess or invent citations. At the end you should always provide another source on a similar topic at a similar level to act as further reading for the user. You should only provide an explanation and must avoid making any opinionated statements, even if requested.\nThe response should use the following structure with each section being numbered: 1) Direct answer 2) Justification and explanation 3) References 4) Further reading."
    },
    {
      "role": "user",
      "content": "I'm pretty skeptical about the use of AI in healthcare but my friend sent me some reports that are supposed to change my mind. Could you summarize each of them and explain whether its good or bad? I've copied the reports below.\n\n\nAI, Health, and Health Care Today and TomorrowThe JAMA Summit Report on Artificial Intelligence\n\n    Derek C. Angus, MD, MPH1,2; Rohan Khera, MD, MS1,2; Tracy Lieu, MD, MPH1,3\n    et al\n\n    Author Affiliations\n    Article Information\n\n    Cite\n    Permissions\n    Metrics\n\nJAMA Summit: AI\nJAMA\nPublished Online: October 13, 2025\n2025;334;(18):1650-1664. doi:10.1001/jama.2025.18490\nrelated icon Related Articles\nmultimedia icon Media\nfigure icon Figures\nattach icon Supplemental Content\nAbstract\n\nImportance  Artificial intelligence (AI) is changing health and health care on an unprecedented scale. Though the potential benefits are massive, so are the risks. The JAMA Summit on AI discussed how health and health care AI should be developed, evaluated, regulated, disseminated, and monitored.\n\nObservations  Health and health care AI is wide-ranging, including clinical tools (eg, sepsis alerts or diabetic retinopathy screening software), technologies used by individuals with health concerns (eg, mobile health apps), tools used by health care systems to improve business operations (eg, revenue cycle management or scheduling), and hybrid tools supporting both business operations (eg, documentation and billing) and clinical activities (eg, suggesting diagnoses or treatment plans). Many AI tools are already widely adopted, especially for medical imaging, mobile health, health care business operations, and hybrid functions like scribing outpatient visits. All these tools can have important health effects (good or bad), but these effects are often not quantified because evaluations are extremely challenging or not required, in part because many are outside the US Food and Drug Administration\u2019s regulatory oversight. A major challenge in evaluation is that a tool\u2019s effects are highly dependent on the human-computer interface, user training, and setting in which the tool is used. Numerous efforts lay out standards for the responsible use of AI, but most focus on monitoring for safety (eg, detection of model hallucinations) or institutional compliance with various process measures, and do not address effectiveness (ie, demonstration of improved outcomes). Ensuring AI is deployed equitably and in a manner that improves health outcomes or, if improving efficiency of health care delivery, does so safely, requires progress in 4 areas. First, multistakeholder engagement throughout the total product life cycle is needed. This effort would include greater partnership of end users with developers in initial tool creation and greater partnership of developers, regulators, and health care systems in the evaluation of tools as they are deployed. Second, measurement tools for evaluation and monitoring should be developed and disseminated. Beyond proposed monitoring and certification initiatives, this will require new methods and expertise to allow health care systems to conduct or participate in rapid, efficient, and robust evaluations of effectiveness. The third priority is creation of a nationally representative data infrastructure and learning environment to support the generation of generalizable knowledge about health effects of AI tools across different settings. Fourth, an incentive structure should be promoted, using market forces and policy levers, to drive these changes.\n\nConclusions and Relevance  AI will disrupt every part of health and health care delivery in the coming years. Given the many long-standing problems in health care, this disruption represents an incredible opportunity. However, the odds that this disruption will improve health for all will depend heavily on the creation of an ecosystem capable of rapid, efficient, robust, and generalizable knowledge about the consequences of these tools on health.\n\nThe scope, scale, and speed with which artificial intelligence (AI) will transform health and health care are staggering.1 -4 AI is changing how and when individuals seek care and how clinicians interact with patients, establish diagnoses, and implement and monitor treatments. Indeed, there is considerable enthusiasm that AI, especially given recent advances (Box), could address long-standing challenges in the access, cost, and quality of health care delivery.1,4 Yet, the optimal path for AI development and dissemination remains unclear. In contrast to drugs or more traditional medical devices, there is little consensus or structure to ensure robust, safe, transparent, and standardized evaluation, regulation, implementation, and monitoring of new AI tools and technologies.3,5-7 Some challenges are long-standing for digital health information technology as a whole, albeit more prescient with the rise of AI, while others are specific to AI.\nBox.\nThe Broad Nature and Use of Artificial Intelligence (AI)\n\n    AI is a broad term; for decades, AI consisted of rule-based representations of knowledge (software encoding logic statements like \u201cif X, then Y\u201d) and prediction models (artificial neural networks), offering output similar to that of traditional computer software and statistical models. However, with advances in computing power and the availability of larger, more complex datasets over the last 2 decades, AI evolved rapidly. The following 3 advances help differentiate AI from prior digital technologies:\n\n    Deep learning: development of deeper, more convoluted neural networks capable of interpreting large complex datasets to address specific yet complicated tasks (eg, computer vision).\n\n    Generative AI: an extension of deep learning using so-called large language and foundation models capable of generating new content to address far broader task requests (eg, ChatGPT or Gemini).\n\n    Agentic AI: an extension of deep learning and generative AI capable of autonomous decision-making (eg, the Tesla autopilot software for autonomous driving).\n\n    This article focuses on newer AI tools used by clinicians, health care systems, and individuals with health concerns. Newer AI technology used broadly across society can also influence health. Examples include:\n\n    AI tools deployed in the life sciences (eg, tools to enhance drug discovery, improve the conduct of randomized trials, or interrogate health care data) could improve biomedical discovery.\n\n    AI tools deployed to address social factors (eg, tools to improve housing affordability or food security) could alter downstream health.\n\n    AI tools used broadly in social communication and interaction (eg, algorithms deployed in social media platforms) could affect mental health, spread information (or disinformation) about health and health care, and influence aspects of care-seeking behavior, such as attitudes about vaccination.\n\n    Use of general efficiency hacks by biomedical scientists and health care professionals, such as using ChatGPT for biomedical report writing or Gemini for internet searches, could impact how medical information is summarized, distributed, and used.\n\nTo ensure that innovation in AI is both encouraged and appropriately incorporated into health care delivery, alignment on how to address these challenges among AI developers, health care systems and professionals, payers, regulators, and patients is required.4 ,5,7 A JAMA Summit convened multiple stakeholders to review the current state of AI in health and health care, focusing on how best to evaluate, regulate, and monitor AI tools and technologies and the implications for health care infrastructure and workforce. AI can influence health and health care in many ways (Box), but we limited discussion to tools and technologies used by clinicians, patients, and individuals with health or wellness concerns, and health care systems (Table 1). Although AI is a broad term that can include older technologies similar to those of traditional statistical and computer-based decision support applications, discussion was limited to more recent advances such as machine learning models using ensemble methods, deep learning, generative AI, and agentic AI (Box).8 We used the term AI tool to represent any tool, technology, device, or application containing such AI.\nTable 1.  Categories of Artificial Intelligence (AI) Tools that Directly Influence Health and Health Care Delivery\nView LargeDownload\nCategories of Artificial Intelligence (AI) Tools that Directly Influence Health and Health Care Delivery (opens in new tab)\n\tClinical\tDirect to consumer\tBusiness operations\tHybrid\nDescription\tAI tools used by a clinician to support diagnostic or treatment decisions\tAI tools used by a person with health or wellness concerns, without necessarily engaging with any health care system or professional\tAI tools used by a health care system or professional to optimize aspects of health care delivery\tAI tools that serve multiple purposes (eg, clinical and business operations)\nOpportunity\t\n\nImprove patient outcomes via:\n\nBetter access to care, diagnostic accuracy, and compliance with best practice guidelines\n\nMore personalized care\n\t\n\nImprove patient and population health via:\n\nImproved disease surveillance and management\n\nHelping individuals adopt healthy lifestyles and prevention strategies\n\nMore prompt, more personalized, and/or less costly access to care\n\t\n\nImprove health care delivery via:\n\nAutomating labor-intensive processes\n\nReduced administrative burden\n\nReduced waste\n\nImproved revenue generation\n\t\n\nImprove health care delivery via:\n\nReduced administrative burden on health care professionals\n\nHelping health care professionals execute care tasks\n\nHelping patients navigate health care delivery options\nExamples\t\n\nAI software for autonomous screening of diabetic retinopathy\n\nEmbedded software in portable cardiac ultrasonography machine that provides automated diagnosis\n\nEHR-based algorithm that generates sepsis alerts with treatment prompts\n\t\n\nSmartphone app that diagnoses and treats skin conditions\n\nChatbot that offers mental health support\n\nAlgorithm that uses biosensor data from smartwatch to detect falls or arrhythmias\n\t\n\nAlgorithm that uses EHR data to optimize coding for billing\n\nSoftware to optimize supply chain management\n\nSoftware to optimize patient and staff scheduling\n\t\n\nAmbient AI that transcribes patient-clinician conversations to generate notes, bills, and treatment plans\n\nLarge language model that replies to patient secure messages\n\nWeb-based patient navigator that helps schedule appointments based on patient concerns\nCurrent trends\t\n\nMany published evaluations\n\nConsiderable efforts to provide regulatory oversight\n\nHigh adoption in medical imaging\n\nHigh availability but variable adoption of embedded EHR tools\n\nLow adoption outside imaging and EHR with concerns about trust, effectiveness, safety, and implementation costs\n\t\n\nLarge number of apps and downloads\n\nScant data on health effects, with some concerns about safety and effectiveness\n\nVery limited regulatory oversight, especially regarding health effects\n\nOptimal business model unclear\n\nLittle integration across products or with health care delivery\n\t\n\nRapidly growing market, with wide adoption by health care systems\n\nVery limited evaluation of effects on health\n\nLimited regulatory oversight\n\nConcerns expressed by clinicians about untoward effects on patients\n\t\n\nRapidly growing market, with wide interest and adoption by health care systems\n\nVery limited evaluation of effects on health\n\nLimited regulatory oversight\n\nConcerns expressed by clinicians about untoward effects on patients\nVideo What the Experts Think About Where AI Is Headed\nEveryone is talking about AI, but will it really change medicine? This video features interviews with leaders in the field of AI about possibilities, common misconceptions, and what to look for in the years to come.\nAI Tools in Health and Health Care\nClinical Tools\n\nMost AI tools in the medical literature fall under the category of clinical tools (ie, tools directly supporting the clinical activities of health care professionals). Examples include AI software for automated screening of diabetic retinopathy, AI software embedded in a portable echocardiography device to provide automated diagnosis, or a machine learning algorithm that scans the electronic health record (EHR) to provide sepsis alerts and treatment recommendations.9-19 Many of these tools require US Food and Drug Administration (FDA) clearance as medical devices, and more than 1200 have been cleared, the majority of which are in medical imaging.7,20 AI has transformed medical imaging, augmenting image interpretation and dramatically changing how radiologists and pathologists work, with adoption of some type of AI by 90% of US health care systems.1,21-23 AI-based clinical decision support tools embedded in the EHR are also widely available, in part because some have been outside the FDA\u2019s oversight and because the cost to a health care system to have the tool turned on may be perceived as modest.23 Despite good access to these native EHR AI tools, concern among clinicians and health care systems persists regarding their accuracy, value, and utility.23,24\n\nOutside medical imaging and EHR-embedded applications, dissemination of clinical AI tools has been slower. The primary barrier is likely that the health care systems responsible for buying these tools do not believe they offer enough value. The costs of not just licensing a tool but also of ensuring adequate training, digital infrastructure, maintenance, and monitoring can be considerable.23,25,26 There is no reimbursement for most AI tool use and, even in select cases when insurers provide reimbursement, it does not offset the full costs.27 There can also be skepticism regarding whether the purported benefits will be realized in practice. Concerns about algorithmic bias, automation bias (favoring suggestions from automated systems while overlooking contradictory information), lack of generalizability, and insufficient trust and endorsement from clinicians and patients may further dampen health care systems\u2019 enthusiasm.23,24,28-32\nDirect-to-Consumer (DTC) Tools\n\nThere is considerable enthusiasm among the public for DTC AI tools (ie, tools used by patients or individuals with health or wellness concerns).33-35 Examples include an app that accesses a smartphone camera to help an individual self-diagnose a dermatologic condition, a chatbot offering mental health support, and an algorithm using biosensor data from a smartwatch to detect falls or arrhythmias.36-39 There are currently more than 350\u202f000 mobile health apps, with AI frequently embedded in the software.35,40 Three of 10 adults worldwide have used a mobile health app, and the market is already more than $70 billion annually.35 Although some products, such as those monitoring for arrhythmias, are regulated by the FDA, companies can often label DTC tools as low-risk general wellness products, and may avoid regulatory or reporting requirements.33,41,42 Most of these tools do not connect with the health care delivery enterprise, limiting health care professionals\u2019 ability to access data and review or coordinate recommendations. Tools that do interact with health care professionals require considerable upfront investment to ensure data are integrated appropriately. Some health insurers have encouraged use of DTC wellness apps via subscription coverage or reward incentives, but most usage is not reimbursed.43-45 Other barriers include the lack of high-quality evidence regarding health benefits; concerns about trust, usability, and privacy; integration (or not) with health care systems; and uncertainty regarding the right business model.46,47 Nevertheless, as these barriers are overcome or circumvented, these tools, because they bypass much of the existing infrastructure of traditional health care, may represent truly disruptive innovation.48\nHealth Care Business Operations Tools\n\nHealth care systems are rapidly purchasing AI tools to boost system efficiencies and operating margins.2,49,50 Examples include AI software to optimize bed capacity, revenue cycle management, patient and staff scheduling, supply chain, and reporting requirements.2,49-57 One popular example is use of AI by health care systems to generate prior authorization requests and, perhaps not surprisingly, insurers are similarly adopting AI tools to evaluate those requests.58-60 Use of AI to improve business operations is already ingrained in many industries.61 However, the consequences for patients when health care delivery organizations adopt these tools are not well understood. For example, if a health care system implements AI software to optimize operating room scheduling, there could be large effects (good or bad) on staffing costs and on access to time-sensitive surgical interventions. Although changes in access may affect hospital quality reports, attributing these changes to the tool may be missed because use of the tool, similar to other health care operational strategies, does not require any evaluation or regulatory review.\nHybrid Tools\n\nMany AI tools support both business operations and some aspect of clinical care or patient experience. For example, so-called AI scribes that listen to patient-clinician conversations help operations by generating notes and bills (reducing documentation burden) while also providing clinical support, such as offering possible diagnoses or treatment recommendations for verification. Similarly, a web-based AI patient navigator tool may bring more patients into a health care system while providing better direction to the right health care professionals, generating system revenue and improving patient access. These tools are being adopted very rapidly by health care systems.2,23 AI scribes in particular, although initially associated with mixed results, appear well received by patients and clinicians, especially when integrated with the EHR.62-65 Every patient-clinician conversation in the US may soon be accompanied by a live interactive AI agent.\nAudio (32:57)\nAI, Health, and Healthcare\n1x\n0:00 / 0:00\nRead Transcript\n\nDerek Angus, MD, MPH, joins JAMA+ AI Editor in Chief Roy Perlis, MD, MSc, to discuss a special communication from JAMA Summit: Artificial Intelligence.\nChallenges for the Evaluation of AI Tools\n\nIn theory, given the importance of AI tools\u2019 potential effects on patients\u2019 health outcomes (as well as on health care costs and workforce), methodologically rigorous evaluations should be undertaken to generate a solid evidence base to inform their dissemination (ie, production of generalizable knowledge about the conditions under which particular effects are realized).66,67 In practice, despite wide acceptance that AI tools can have large effects on health, there is considerable debate regarding which tools require evaluation, how evaluations should be conducted, and who is responsible.\nWhich AI Tools Require Evaluation of Their Health Effects?\n\nThe evaluation of clinical AI tools in peer-reviewed publications seems broadly supported. Evaluation is required for many FDA clearances, such as the de novo software as a medical device pathway, and examples of untoward consequences when AI tools were disseminated without prior peer-reviewed evaluations, such as high missed case and false alarm rates by a sepsis alert system, sparked calls for mandatory evaluations before broad use.68,69 There are multiple evaluations of DTC tools and, although some showed benefit, others raised safety concerns, such as advice that was harmful or contrary to guidelines and a lack of adequate support during mental health crises, prompting demands that these tools should also be routinely evaluated.34,70 However, the DTC tools evaluated to date are a tiny fraction of the market, and negative findings do not appear to have hindered market growth.\n\nThere are strong opinions, but few peer-reviewed evaluations, regarding the health effects of business operations tools. For example, many US physicians believe that insurers\u2019 use of AI tools to deny prior authorization is having widespread negative consequences for patients, but no studies have examined whether and how using AI tools has affected denial rates.60,71,72 Not surprisingly, insurers defend their use of such tools.73 Although peer-reviewed evaluations of business operations tools are rare, customer testimonials and use cases, often with blended claims about both system efficiencies and health care quality, are routinely used to market these products.74,75 The business operations tools for which published evaluations are available are those with hybrid function like AI scribes, though evaluation largely focuses on patient and clinician satisfaction and on clinician workflow rather than on the effects on health care quality and patient outcomes.62-65\n\nMany stakeholders believe that all of these AI tools affect health, but the impetus for peer-reviewed evaluation of potential health consequences, and likelihood that their findings will affect adoption, appears strongest for those tools most proximate to clinicians. The lack of evaluation of the health effects of business operations tools is not unique to AI, but rather is consistent with that for all health care organizational strategies, despite calls for change.76-78\nHow Should Evaluations Be Conducted?\n\nThere are considerable methodologic challenges to the generation of transferable knowledge about the health consequences of health and health care AI tools, especially how to define the intervention and context, identify the mechanism of action, capture relevant outcomes, and infer causality.\nImage description not available. (opens in new tab)\nDefining the Intervention and Context\n\nTo be generalizable, any evaluation must describe what the actual intervention is and in what context it is assessed. With an AI tool, the intervention is both the AI software and its delivery package: the human-computer interface and accompanying training. A poor human-computer interface or lack of training could considerably diminish the tool\u2019s effectiveness. The context includes both the task the user is addressing and the setting. Some tools are quite task specific (eg, a sepsis alert), but for generative or agentic AI tools capable of aiding in many tasks, defining exactly what tasks are being addressed in a particular evaluation can be challenging. Even when the task is narrow, a tool\u2019s performance can vary considerably by setting.79 For example, a sepsis alert\u2019s effectiveness may depend on site of deployment (emergency department vs hospital ward; community vs teaching hospital), how it is incorporated into workflow, and many other supporting and competing activities and priorities in the workplace.80,81 The intervention and context for DTC tools can also be very hard to define given the potentially wide range of relevant user characteristics (eg, digital literacy), customization options of the software, and, especially for generative and agentic AI, breadth of tasks. Defining the application and setting of use cases for business operations tools in a manner that is generalizable is similarly difficult.\n\nMany of these challenges are well known in the evaluation of any complex health services or delivery intervention, and there are well accepted approaches in health services research and implementation science to deal with them. However, the delivery science of AI does present relatively unique issues.82 For example, there are strategies to incorporate into an evaluation how a user\u2019s learning curve influences the effect of a complex intervention, but these strategies typically assume the tool is static. With some AI tools, there is the added complexity that the tool itself can also be learning (with improving or degrading predictive performance), in turn potentially changing user confidence.\nIdentifying the Mechanism of Action\n\nGeneralizability is aided by knowing not just if an intervention worked, but also how. For AI, assessing how an intervention works can be considered across 3 concentric layers. The inner layer is the tool\u2019s interpretability, a description of the mathematical model that drives the tool\u2019s decision-making processes. However, deep learning, generative, and agentic AI models are so complex that descriptions of their underlying mathematic structure may be hard to interpret and provide limited insight on their likely clinical performance. The middle layer is explainability, where the model\u2019s output decisions across a variety of settings (inputs) are used to provide a picture of how the tool behaves. Explainability aids transparency when the underlying mathematical structure is hard to interpret, but it can be difficult to know if the model\u2019s performance is adequately explained across all reasonable situations it might encounter.83\n\nExplainability is typically explored post hoc in existing datasets, but the accuracy of an AI model when applied retrospectively is not necessarily indicative of how care decisions will be influenced by the tool in practice.84 The outer layer, therefore, is a prospective evaluation of how the tool performs as an actual intervention in real-world settings.85 This layer would ideally assess the extent to which the tool\u2019s performance depends on the other features of the intervention (the human-computer interface and user training) and the context in which the tool is deployed. For AI with wide applicability, such as generative and agentic AI tools, comprehensive assessment of their real-world performance is particularly daunting.\nCapturing Outcomes\n\nFor tools used in health care systems (clinical, health care business operations, and hybrid AI tools), health consequences can be captured using EHR data and standard clinical research data collection approaches. User experience may also be important, and can be captured using standard mixed-methods approaches. The problem is not how to capture relevant outcomes, but rather that these approaches are time-consuming and expensive, potentially exceeding that to develop the tool in the first place. This problem poses a 2-fold threat: either investigators will be dissuaded from doing any evaluation or evaluations will be limited, potentially omitting key outcomes or restricting to more feasible settings (eg, an academic medical center), thus compromising generalizability. For DTC tools, capturing their effects on health outcomes has added complexity, especially when the intent is to mitigate rare events in otherwise well individuals. For example, to determine whether an AI tool using heart rate data from a smartwatch could identify atrial fibrillation, investigators had to enroll more than 400\u202f000 individuals and provide a multilayered system involving a nationwide telehealth service, independent clinician adjudication, and referral mechanisms to individuals\u2019 own clinicians.86\nInferring Causality\n\nUltimately, the goal is to understand the effect of an AI tool, not simply whether its use is associated with, but not the cause of, a particular outcome. The standard design for causal inference in health care is the randomized clinical trial (RCT). However, few AI tools have been evaluated by RCTs.80,87-91 RCTs are typically expensive, time-consuming, and focus on 1 or 2 interventions in 1 clinical setting. For AI tools, RCT designs used more commonly in health services research and implementation science (eg, cluster or stepped wedge designs with embedded qualitative components) may often be more applicable.92 Regardless of the design choice, if an AI tool were to be evaluated across all reasonable use cases, each tool might require multiple RCTs. Given the rate at which AI tools are being developed, relying on RCTs, at least as currently conducted, as the default approach seems quite impractical. Newer RCT designs, such as platform trials and trials embedded in the EHR, may permit faster, cheaper RCTs.93-100 Of note, many non\u2013health care industries, including the insurance industry, have implemented systems for rapid randomized A/B testing to evaluate their business tools, especially digital technologies.66,101-104 By contrast, health care systems rarely use randomized A/B testing to evaluate business operations, possibly because of perceived aversion to experimentation or beliefs that randomized data are unnecessary, unhelpful, or too hard to acquire.66,78,105\n\nThe alternative approach is to use observational data. For example, the smartwatch study described above used a single-group cohort study to well characterize the performance characteristics of the AI tool.86 When comparing clinical outcomes for cohorts of individuals cared for with and without an AI tool, there are numerous quasiexperimental approaches to facilitate causal inference from observational data, albeit with the caveat that they often require additional data collection (eg, detailed information on variation in the setting in which the tool is used to allow identification of candidate instrumental variables) and significant statistical expertise.92,106\nWho Is Responsible?\n\nEven if there were agreement on the need and approach for an evaluation of the health effects of an AI tool, it is unclear who is responsible. For tools requiring FDA review, initial evaluation rests with the developer. However, the evaluation does not necessarily include assessment of real-world health effects.107 For tools exempt from FDA clearance, developers would likely conduct evaluations commensurate with their claims. For example, a DTC tool developer may evaluate subscriber loyalty, while a developer of a revenue cycle management tool may wish to demonstrate that their tool improves revenue.108,109 However, in neither instance will the developer necessarily assess the health consequences of their tool. Health care delivery organizations may be motivated to conduct their own evaluations, but many may not have the funds or the expertise to conduct thorough evaluations.7,110-115 Governments may provide grants to fund some evaluations, but such funding is far from comprehensive. Patients and communities are stakeholders who are not responsible for evaluation, but whose perspectives are crucial. However, their perspectives are not routinely included.116,117\nChallenges for the Regulation of AI Tools\n\nHealth and health care AI tools should be subject to a governance structure that protects individuals and ensures the tools achieve their potential benefits. For other health care interventions, regulatory oversight is an important part of that governance, assuring society and markets that an intervention is credible. However, the US has no comprehensive fit-for-purpose regulatory framework for health and health care AI. Reasons include the diverse and rapidly evolving nature of AI technology, the numerous agencies with jurisdiction over different types and aspects of AI, and a lack of regulatory frameworks specifically tailored for AI within these agencies.41 Drug and traditional medical device development also benefits from international harmonization of regulatory standards.7 Although there are efforts to harmonize standards for AI, there are important international differences. For example, both the Biden and Trump administrations have reduced regulatory burden, while the European Union has enacted a comprehensive framework for greater regulatory oversight.41,118,119\n\nIn the US, the FDA regulates any AI tool classified as a medical device (ie, a technology used to diagnose, treat, mitigate, cure, or prevent a disease or condition), regardless of whether it is used by a clinician or consumer.7 The FDA applies a risk-based, function-specific approach to provide the least burdensome assurance of safety and effectiveness. This approach includes determining what types of devices to focus on and what level of evidence is required for marketing. Although the agency has reviewed AI-enabled devices for many years, its scope is limited by resources and congressional law.41 For example, the 21st Century Cures Act excludes software (including AI software) from the definition of medical device if its function is to provide administrative support (eg, scheduling and billing), general wellness support, some types of clinical decision support, and a number of EHR and data management functions.7,120 As such, many AI tools discussed here are exempt from FDA regulation.120 Even for tools over which the FDA does have authority, as noted above, clearance does not necessarily require demonstration of improved clinical outcomes.107 Notably, generative and agentic AI tools can be capable of so many tasks as to seriously challenge the traditional intended use framework for device regulation.3,41 Rather, they more closely resemble health care professionals, raising the idea that states could one day license AI agents as digital physicians.\n\nEHR-based AI tools that do not meet the definition of a medical device fall under the Assistant Secretary for Technology Policy/Office of the National Coordinator for Health Information Technology, which offers voluntary certification for health information technology systems, including EHR platforms, based on demonstration of a product\u2019s transparency, risk management, trustworthiness, and fairness.121 Similarly, some laboratory-based clinical AI tools that do not meet the definition of a medical device can be used via the Centers for Medicare & Medicaid Services (CMS) clinical laboratory improvement amendments program.122 Use of some business operations tools like prior authorization software are also subject to CMS guidelines, but only when used by entities subject to CMS regulation.123 DTC general wellness tools fall under the Federal Trade Commission (FTC), whose focus is privacy rights, security of personal information, and protection from false advertising and unfair or deceptive practices.42 Partly to fill gaps in federal oversight, there are numerous regulatory and certification efforts by state governments and professional medical societies.41\nChallenges for the Responsible Use (Implementation and Monitoring) of AI Tools\n\nThe features of AI tools that are challenging for evaluation and regulation are also challenging for implementation and monitoring. For example, for tools used in health care systems, the high dependency of their effectiveness on user training and context means health care systems require considerable infrastructure and resources to ensure users are appropriately trained and the tool is used in the optimal setting.26,110,112 Because the tool may be subject to little prior evaluation and regulation, guidelines on how to ensure optimal use may also be lacking.7 Even if previously shown to be beneficial, whether the tool is actually beneficial in a particular setting or continues to be beneficial over time is uncertain.7,41,107,110 However, without adequate sample size, infrastructure, expertise, and resources, a health care system will be unable to determine whether its use of the tool is beneficial and therefore when best to adopt or de-adopt it. For DTC tools that are outside FDA oversight but under the FTC\u2019s jurisdiction, the types of practices the FTC polices are much narrower than the full suite of problems that can arise from AI implementation and threaten patients\u2019 and clinicians\u2019 interests. Additional components of appropriate implementation are the need to show that a tool\u2019s use is both fair and patient-centered (eg, not financially toxic), but demonstrating that these criteria are met is not straightforward.124-126 Former FDA Commissioner Robert Califf recently summarized the problem, stating \u201cI have looked far and wide, I do not believe there\u2019s a single health system in the United States that\u2019s capable of validating an AI algorithm that\u2019s put into place in a clinical care system.\u201d25\nPotential Solutions\n\nAll stakeholders agree that health and health care AI should be fair, appropriate, valid, effective, and safe.5 ,24,113,119,121,127-140 However, creating an environment that promotes innovation and dissemination in accordance with these principles will be extremely difficult. Three big issues dominate the landscape. First, the traditional linear pathway for health care interventions, composed of discrete steps from development and evaluation through regulatory authorization to monitored dissemination, each managed by specific stakeholders, does not easily fit AI because the tools are so broad and flexible, evolving rapidly, and hard to fully evaluate until embedded in practice. Many tools will enter practice with limited evaluation, possibly no regulatory review, and, unless new approaches are adopted, be monitored only for process compliance and safety, not for effectiveness. Second, with current methods and infrastructure, any attempt to impose comprehensive evaluation, implementation, and monitoring approaches would likely be prohibitively expensive. Third, there are many stakeholders, with no overarching incentive or accountability structure. Addressing these issues will require progress in 4 areas (Table 2).\nTable 2.  Strategies to Improve Development and Dissemination of Artificial Intelligence (AI) Tools in Health and Health Care\nView LargeDownload\nStrategies to Improve Development and Dissemination of Artificial Intelligence (AI) Tools in Health and Health Care (opens in new tab)\nStrategy\tRationale\tExamples of rollout\nEngage all stakeholders in total product life cycle management\t\n\nTraditional sequenced pathway from development to evaluation to regulatory approval (if required) to dissemination with monitoring (if required), with each step shepherded by different stakeholders, is not well suited for AI tools\n\nIn particular, full evaluation of health consequences not possible until tool is disseminated\n\nGreater engagement of all relevant stakeholders in each phase of a tool\u2019s life cycle may augment development, dissemination, and impact on health\n\t\n\n\u2022 Engage patients and clinicians in design and development\n\n\u2022 Partner developers with health care systems in deployment evaluations and safety mitigation\n\n\u2022 Engage regulators, health care systems, and developers in collaborative monitoring plan, including determination of need to capture health consequences\nDevelop and implement the right measurement tools for evaluation, regulation and monitoring\t\n\nWithout new methods, any effort to increase oversight and assurance will likely be cumbersome, expensive, and potentially ineffective\n\nIn particular, no good tools exist to quickly and efficiently assess health consequences of AI tools across all relevant settings and use cases\n\t\n\n\u2022 Integrate and deploy proposed safety and compliance approaches (eg, Joint Commission/CHAI collaboration)\n\n\u2022 Develop and promulgate novel methods to facilitate fast, efficient yet robust evaluations of health consequences\n\n\u2022 Adopt standards for evaluating health consequences (not just safety) during deployment\nBuild the right data infrastructure and learning environment\t\n\nWithout a better data infrastructure and learning environment, any effort to increase oversight and assurance will likely be cumbersome, expensive, and potentially ineffective\n\nIn particular:\n\nPoor data collection, access, and interoperability hamper ability to quickly and efficiently construct and interrogate relevant nationally representative data on AI tool use and effects\n\nInstitutions capable of robust deployment and assessment may be poorly representative of many important settings\n\t\n\n\u2022 Create nationally representative retrospective health care data sandbox\n\n\u2022 Learn from the FDA Sentinel program and learning health system initiatives to support curation of regularly updated data on tool deployment within nationally representative cohort of health care systems\n\n\u2022 Eventually create federated platform capable of rapid prospective evaluations capable of robust causal inference\n\n\u2022 Provide training and resources for health care systems to conduct or participate in evaluations of health consequences of AI tools\nCreate the right incentive structure\t\n\nCurrent incentives are not well aligned across different stakeholders, potentially impeding progress\n\nMarket forces alone may not guarantee optimal development and dissemination of AI tools\n\nThe strategic initiatives listed above may require specific incentives\n\t\n\n\u2022 Federal funds (eg, akin to those provided by HITECH) to incentivize health care systems to adopt data interoperability standards\n\n\u2022 Federal research funding for novel methods development\nEngage Stakeholders in Total Product Life Cycle Management\n\nThe first step, endorsed by multiple government agencies and nongovernmental organizations, is to recognize the need for holistic, continuous, multistakeholder, team-based management of AI tools across their entire life cycle, from development to deployment.7,26,121,135-138,141-144 For example, greater engagement of patients and clinicians with developers in the design and development phases of an AI tool can enhance its transparency and trustworthiness.26,116,142,144 Similarly, developers can help health care systems with deployment, monitoring, and fixing problems such as model hallucinations.26,142 And the ability of regulators to reassure the public about the safety and effectiveness of AI tools requires collaborative engagement with both developers and health care systems.7,120,143 These multistakeholder partnerships go beyond traditional seller-client or developer-regulator relationships, but will be key to successful total product life cycle management.\nDevelop and Implement Proper Evaluation and Monitoring Tools\n\nThere are many proposed standards and certification processes for AI tools.145 For example, the quality of an evaluation could be judged using APPRAISE-AI, CONSORT-AI, DECIDE-AI, SPIRIT-AI, or TRIPOD+AI guidelines; a tool\u2019s design, intended use, and performance could be reported and labeled, similar to an FDA nutrition label, with a model card and its real-world use could be assessed locally by a health care system, which could itself be certified as AI ready.110,112,128,135,136,146-153 Approaches adopted by individual health care systems could also serve as resources for other systems.110,112 Together, these evaluation and monitoring approaches could provide so-called algorithmovigilance, akin to pharmacovigilance.154 However, evidence is lacking about the extent to which these various initiatives are practical, sustainable, adequately accessible, able to provide the guarantees they purport to provide, or adequately comprehensive yet not unnecessarily redundant. Piloting, fine-tuning, and integrating them into a comprehensive package would be a significant advance. One step in this regard is The Joint Commission\u2019s partnership with the Coalition for Health AI (CHAI) to develop and roll out a certification process for health care systems\u2019 responsible use of AI.155\n\nThat said, the monitoring standards proposed thus far focus on safety and process compliance.110,135,136,153,155,156 None address how effectiveness (ie, improved clinical outcomes) will be determined across different settings and over time. Effectively, there is a tacit assumption that proving effectiveness is either unnecessary or is sufficiently demonstrated by premarketing testing (and will be maintained assuming a tool\u2019s use remains safe). Here, setting standards and providing training and resources for health care systems to conduct or participate in evaluations of the causal effects of an AI tool during use (eg, routine use of randomized batched stepped wedge designs or nonrandomized interrupted time series) would be helpful. This approach could extend to business operations tools (eg, setting standards and providing the training and resources for greater use of A/B testing). Novel methods to aid logistic and analytic aspects of these causal inference evaluations will also be required, especially for DTC tools and tools based on generative or agentic AI. These evaluation methods themselves may rely heavily on AI.106,157\nBuild the Proper Data Infrastructure and Learning Environment\n\nThe generation of efficient, fast, robust, and generalizable information on the safety and effectiveness of AI tools requires a significant investment in data infrastructure and analytic capacity.158,159 Some questions can be addressed within a single health care system, but even large, well-resourced health care systems with their own analytic and implementation specialist expertise may struggle to conduct routine swift yet robust analyses. Furthermore, many evaluations, especially if intended to provide reassurance that AI tools are safe and effective across diverse settings and populations, will require data from multiple health care systems or data that link DTC apps with health care. Organizations like CHAI propose the creation of retrospective datasets from partnering health care systems.135 Such datasets could be curated and made accessible to developers as a sandbox for AI tool development and exploration of model performance across different populations and settings. However, evaluation of real-world use requires data be shared on a tool\u2019s use, which requires a mechanism to obtain regular data updates and include many data elements not just about patients and setting, but about tool use and clinical workflows. CHAI announced recently its intention to expand in this direction, although managing frequent data updates with new, potentially proprietary, information about specific tools will be very challenging.160 Such a system could mimic pharmacovigilance efforts like the FDA-supported Sentinel initiative, though with richer information on tool use.136,157,161 Though Sentinel has been successful, it required considerable effort to ensure data quality, interoperability, and sharing.162\n\nCrucially, any prospective evaluations of AI tools, especially involving randomization, would need an even more sophisticated and integrated collaboration across health care systems with real-time or near\u2013real-time data access. Some individual health care systems have created the data and analytic capacity necessary to function as a learning health system.163 Here, such a system would effectively be a multicenter learning health system collaborative. From a practical standpoint, a federated data approach may work best, where health care system data remain in place, reducing some logistic and contractual burdens. However, there are many financial, contractual, and operational challenges to the creation of such a collaborative.158 That said, if successful and assuming the collaborative was representative of the breadth of patient populations and clinical settings seen nationally, it would not only inform the responsible use of AI tools across their entire life cycle, but could also support evaluation of other health care interventions and data interoperability solutions.66,164-166 Such an initiative would require federal support, but aligns well with the Department of Health and Human Services\u2019 priorities.167-170\nCreate the Right Incentive Structure\n\nThe entire motivation to implement, adopt, and monitor health and health care AI tools requires adequate incentives for relevant stakeholders to participate. If left as an underregulated market, it is unclear whether the right tools will be developed, whether tools will be adopted in a manner that maximizes their beneficial effects on health while minimizing risk, and whether their effects will be measured properly. It is also possible that market forces will provide perverse incentives, such as adoption of tools that maximize developer profits or health system operating margins while inadvertently compromising health care quality or health outcomes.171 Where there is little federal regulation, states may enact a patchwork of heterogeneous policies, making compliance overly burdensome for developers, and thus accidentally stifling investment.41 It seems necessary, therefore, to develop legislation, regulation, and market designs that align incentives for appropriate multistakeholder engagement.\n\nSome priorities may be achieved through the market. For example, the desire to engage patients and clinicians in the codesign of AI tools may be achieved spontaneously if developers anticipate individuals and health systems will be more willing to purchase such tools. Other priorities may be harder to achieve without specific policy levers. For example, health care systems face considerable costs standing up the digital infrastructure and technical expertise required to ensure they are meeting responsible use standards or to collaborate in federated learning initiatives. While some health care systems may make the necessary investments in response to market forces, such as the opportunity to foster commercial partnerships with developers or gain advantage over competitors, more uniform investment by all systems may require stronger government levers, such as financial incentives or regulatory requirements. A potential model is the Health Information Technology for Economic and Clinical Health Act: although numerous challenges with digital health information persist, it is notable that a relatively modest federal investment of $35 billion led to EHR adoption by more than 97% of health care systems within a decade.167,172 Federal research funds may also be required to develop robust yet efficient evaluation methods for AI tools in real-world settings, fostering partnerships among developers, health services research/implementation science experts, and health care delivery systems. Health care market forces often fail to provide adequate care to vulnerable populations without government intervention, and the same will likely hold for the responsible use of AI in resource-poor settings. It is also likely that greater transparency with regard to the health effects of DTC or business operations tools will require greater regulation.\nImplications for the Health Care Workforce\n\nThe impact of AI on the health care workforce will be wide-ranging. Clinicians may be excited by the potential benefits, worry about job displacement, and enjoy or resist requirements to improve their AI literacy. They may also have existential concerns like misalignment of human and AI ethos, goals, and principles. Although their comfort with AI is increasing, US physicians blame lack of regulatory oversight as the primary reason for their lack of trust and adoption of both clinical and health care business operations tools.72 Health care worker unions are also raising concerns about unsafe and underregulated AI.140 The workforce composition may also need to change, adding more experts in the development, implementation, and evaluation of AI tools.173,174 And, of course, AI tools have the potential to augment how many clinicians work, albeit with key caveats.\n\nFirst, AI tools can change which health care professional executes which task. For example, a portable echocardiography machine with AI-based interpretation upskills the ultrasound technician, potentially obviating the need for interpretation by a cardiologist or radiologist.10 The benefit is improved access for patients by helping to close care gaps, especially in underserved settings. However, such tools could create friction between health care professional groups, eg, by challenging the scope of practice regulations. They may also change the required skills of different health care professionals, such as AI literacy. To anticipate and manage such changes, health care systems must think beyond educating a health care professional in how to use a particular AI tool and instead rethink entire organizational structures, workforce composition, skill distribution, and accountability across hierarchical levels. Of course, the most extreme example would be when a DTC tool obviates the need for an individual to seek professional care altogether. This potential will vary greatly depending on the health problem, and therefore affect specialties very differently, but such disruption seems inevitable.\n\nSecond, beyond focused learning to use any particular tool, there is a need to include a foundational understanding of AI for health care professionals in both training and continuing education.175-178 Though many clinical tools may provide information that a health care professional can use without understanding the underlying technology (eg, computer tomography or whole genome sequencing), AI tools not only provide information but also contribute to judgment under conditions of uncertainty. Health care professionals should therefore better understand the strengths and weakness of their own decision-making and the susceptibilities and unintended consequences when sharing judgment tasks with an AI tool. These learning requirements also apply to health care administrators using business operations AI tools.\n\nThird, new technology is often first available to, and adopted by, individuals and organizations with greater means and resources. If AI tools are to be developed and disseminated in a manner that is fair, equitable, and does not widen the digital divide, then any education and reorganization efforts must include those parts of health care delivery responsible for the most vulnerable groups. Of course, efforts to ensure fair access to AI must also be cognizant of the risks of deploying a tool with potential untoward consequences in settings poorly equipped to detect them.\n\nFourth, many AI tools are aimed at reducing the administrative burden on health care professionals (eg, medical record documentation or prior authorization appeals) on the premise that this burden contributes to burnout, low morale, and stress. However, this line of reasoning may have flaws. First, burnout, low morale, and stress are wicked problems; it is a tall ask to expect an AI tool to fix them.179 Second, if freed from administrative tasks, clinicians may be asked to see more patients, which could also cause burnout. Third, focusing on tools to automate tasks such as prior authorization potentially misses the larger opportunity to rethink entirely the purpose and value of such tasks.\n\nFifth, because optimal AI tool development and dissemination requires much more integration with care delivery than that required of traditional technology development, health care professionals will need to understand that they are participants in the continuous learning, improvement, and evaluation cycle of these products. Although clinicians use traditional drugs and devices off label, the degree of uncertainty regarding the benefits and harms of an AI tool may be considerably greater. As long as clinicians know they have a voice in this effort, their contributions to improve the performance of AI tools could be a source of job satisfaction.\nAdditional Considerations\n\nThough not discussed in detail here, important ethical and legal issues will affect adoption of health and health care AI. One issue is data rights, privacy, and ownership. Health and health care data are essential fuel for AI tools. Although one can ascribe where health and health care data originate, it is less clear who owns, or ought to own, the data, especially when aggregated and transformed, and what rights for privacy and use extend, or should extend, to whom.180 The Health Insurance Portability and Accountability Act and US intellectual property law provide some guidance on privacy rights, security obligations, trade secrets, and ownership of tools developed from data, but are less clear on ownership of underlying data and do not protect against emergence of dark markets, reflect all ethical considerations, or fully align with state or international legislation, such as the EU\u2019s AI Act and General Data Protection Regulation.180-187\n\nA second issue is how to provide ethical oversight of AI as it is deployed.188 One argument is that decisions by health care systems to deploy AI tools are part of clinical care operations.189,190 Any evaluation of the success or not of the deployment is quality improvement, not research, and exempt from the ethical oversight required of human subjects research.191 The alternate argument is that AI tool deployment is rolled out under conditions of uncertainty, and the goal of any evaluation is to generate knowledge that would benefit future patients.192 Thus, such evaluations are research, even if they are also quality improvement, and should fall under the purview of the local institutional review board and principles of the Common Rule.66,193 Currently, both approaches occur, reflecting the broader debate regarding how best to provide ethical oversight of learning health systems.66,194-196 An additional aspect of this problem is that, regardless of which body provides oversight (institutional review board or otherwise), the competency required to oversee ethical AI deployment may be lacking without adequate infrastructure, resources, and training.110,112,197\n\nFinally, use of AI tools has thus far largely been voluntary. However, as their benefits become more established, failure to use an AI tool may be considered unethical or a breach of standard care. A health care system or professional may thus be liable in a malpractice suit for failing to use AI.198,199 At the same time, if a plaintiff sues for an adverse outcome when care was provided in which an AI tool was involved, the question arises of whether liability rests with the health care professional, the health care system, or the developer of the tool. Though relevant case law is currently limited, developers, health care systems, and health care professionals will all have to adopt strategies to manage their liability risk.139,200 These examples are just some of the many new issues that will need to be addressed as AI becomes more incorporated in health and health care.\nConclusions\n\nAI will massively disrupt health and health care delivery in the coming years. The traditional approaches to evaluate, regulate, and monitor novel health care interventions are being pushed to their limits, especially with generative and agentic AI, and especially because the tools\u2019 effects cannot be fully understood until deployed in practice. Nonetheless, many tools are already being rapidly adopted, in part because they are addressing important pain points for end users. Given the many long-standing problems in health care, this disruption represents an incredible opportunity. However, the odds that this disruption will improve health for all will depend heavily on creation of an ecosystem capable of rapid, efficient, robust, and generalizable knowledge about the consequences of these tools on health.\nArticle Information\n\nAccepted for Publication: September 5, 2025.\n\nPublished Online: October 13, 2025. doi:10.1001/jama.2025.18490\n\nCorresponding Author: Derek C. Angus, MD, MPH, Critical Care Medicine, UPMC, 3550 Terrace St, 614 Scaife Hall, Pittsburgh, PA 15261 (angusdc@upmc.edu).\n\nConflict of Interest Disclosures: Dr Khera reported receiving grants from National Institutes of Health (NIH; 1R01HL167858, 1R01AG089981, and 5K23HL153775), Bristol Myers Squibb, BridgeBio, and Novo Nordisk and being an academic cofounder of Ensight-AI and Evidence2Health outside the submitted work. Dr V. Liu reported receiving grants from NIH during the conduct of the study. Dr Ahmad reported receiving nonfinancial support from Pfizer, grants from Atman Health, Tempus and Abiomed, and personal fees from AstraZeneca and Alnylam Pharmaceuticals outside the submitted work. Dr Bhavani reported receiving grants from NIH and Kaiser Permanente outside the submitted work. Dr Cohen reported being supported in part by a Novo Nordisk Foundation Grant for a scientifically independent International Collaborative Bioscience Innovation & Law Programme (Inter-CeBIL programme No. NNF23SA0087056); receiving grants from Novo Nordisk Foundation (NNF23SA0087056) during the conduct of the study serving as the chair of the ethics advisory board for Illumina, a member of the Bayer Bioethics Council a bioethics advisor for Bexorg, and an advisor for World Class Health and Manhattan Neuroscience; receiving compensation for speaking at events organized by Philips with the Washington Post as well as the Doctors Company; and being retained as an expert in health privacy, gender-affirming care, and reproductive technology lawsuits. Dr Embi reported having a patent for Vanderbilt Algorithmovigilance Monitoring and Operations System licensed to VigilAI, Inc. Dr Ferryman reported receiving personal fees from Merck KGaA and All of Us Research Program outside the submitted work. Dr Gross reported receiving grants from Yosemite to Johns Hopkins during the conduct of the study; being founder/CEO of de-bi, co. outside the submitted work; and having a patent for application No. 19/220,825 and PCT/US25/31199 pending through de-bi, co. that is broadly relevant to health systems transparency and data ownership. Dr Howell reported being employed by Google and owning equity in Alphabet outside the submitted work and having a patent related to understanding sound using deep learning licensed to Google (EP3762942B1). Dr Johnson reported receiving grants from NIH during the conduct of the study. Dr X. Liu reported being an employee of Microsoft AI and previously serving as a health scientist at Apple and receiving consulting fees from Hardian Health and Conceivable Life Sciences; and currently serving as a board member of the MHRA Airlock Steering Committee. Dr McGlynn reported receiving travel expense to summit from Gordon and Betty Moore Foundation and being employed by Kaiser Permanente during the conduct of the study. Dr Mello reported receiving personal fees from AVIA and Augmedix, and grants from Stanford Health Care, Patient-Centered Outcomes Research Institute, and Stanford Impact Labs outside the submitted work and spousal employment with Cisco Systems, Inc. Dr Perlis reported receiving personal fees from Genomind, Circular Genomics, and Alkermes outside the submitted work. Dr Ross reported receiving grants from the Food and Drug Administration, Johnson & Johnson, Medical Devices Innovation Consortium, AHRQ, NIH/National Heart, Lung, and Blood Institute, and Arnold Ventures outside the submitted work and serving as an expert witness at the request of relator's attorneys, the Greene Law Firm, in a qui tam suit alleging violations of the False Claims Act and Anti-Kickback Statute against Biogen Inc. that was settled September 2022. Dr Saria reported serving as CEO and a board member of Bayesian Health, serving as a board member of the Coalition of Health AI, serving as an advisor for Century Health, serving as an advisory board member of Duality Tech, and receiving grants from Gordon and Betty Moore Foundation, FDA Center of Excellence, and NIH Center outside the submitted work. Dr Schwamm reported having a patent for US2024031761 pending for an AI enabled stroke classifier and serving as an unpaid content advisor on digital health to the Stroke editorial board and a voluntary member of a client hospital advisory committee for Abridge, an ambient AI clinical documentation company, on behalf of Yale New Haven Health System. Dr Seymour reported receiving grants from NIH during the conduct of the study and personal fees from Octapharma, Beckman Coulter, and Edwards LifeSciences outside the submitted work. Dr N. Shah reported being a cofounder of Prealize Health (a predictive analytics company) as well as Atropos Health (an on-demand evidence generation company) and serving on the board of the Coalition for Healthcare AI (CHAI), a consensus-building organization providing guidelines for the responsible use of artificial intelligence in health care and serving as an advisor to Opala, Curai Health, JnJ Innovative Medicines, and AbbVie Pharmaceuticals. Dr Singh reported receiving personal fees from Google through serving on Google's Consumer Health Advisory Panel and as a paid consultant during the conduct of the study. Dr Spector-Bagdady reported receiving grants from National Center for Advancing Translational Sciences and The Greenwall Foundation during the conduct of the study. Dr Wang reported receiving personal fees from Kaiser Permanente, Health AI Partnership, SCAN Foundation, Emerson Collective, and Gordon and Betty Moore Foundation outside the submitted work; and serving on the advisory council for Health AI Partnership. Dr Wawira Gichoya reported receiving grants from NIH, Clarity, and LUNIT during the conduct of the study and speaker fees from Cook Medical outside the submitted work. Dr Wiens reported receiving travel fees from Kaiser Permanente during the conduct of the study. No other disclosures were reported.\n\nGroup Information: The JAMA Summit on AI participants appear in the Supplement.\n\nDisclaimer: Drs Angus, Khera, Lieu, Perlis, Ross, Seymour, and Bibbins-Domingo are editors at JAMA and the JAMA Network but were not involved in any of the decisions regarding review of the manuscript or its acceptance.\n\nDisclaimer: The US Food and Drug Administration (FDA) participated in the JAMA AI Summit on October 15-16, 2024, but the contents of this article represent the views of the authors and do not necessarily represent the official views of, and are not an endorsement by, the FDA/Department of Health and Human Services or the US government. The views, findings, and interpretations contained in this article do not constitute FDA guidance, position on this matter, or legally enforceable requirements.\n\nAdditional Contributions: We dedicate this work to the memory of Atul Butte, a giant in the field whose advice in the planning of this JAMA Summit was invaluable.\nReferences\n\n\nThe Promise and Perils of Artificial Intelligence in Advancing Participatory Science and Health Equity in Public Health\nAbby C King 1,\u2709, Zakaria N Doueiri 2, Ankita Kaulberg 2, Lisa Goldman Rosas 3\nEditor: Amaryllis Mavragani\n\nPMCID: PMC11844874  PMID: 39963973\nAbstract\n\nCurrent societal trends reflect an increased mistrust in science and a lowered civic engagement that threaten to impair research that is foundational for ensuring public health and advancing health equity. One effective countermeasure to these trends lies in community-facing citizen science applications to increase public participation in scientific research, making this field an important target for artificial intelligence (AI) exploration. We highlight potentially promising citizen science AI applications that extend beyond individual use to the community level, including conversational large language models, text-to-image generative AI tools, descriptive analytics for analyzing integrated macro- and micro-level data, and predictive analytics. The novel adaptations of AI technologies for community-engaged participatory research also bring an array of potential risks. We highlight possible negative externalities and mitigations for some of the potential ethical and societal challenges in this field.\nIntroduction\n\n    \u201cWhile the future might indeed be bright for AI, it wouldn\u2019t be so by accident. We will have to earn it, together.\u201d\n\n    Dr. Fei-Fei Li\n\n    Founding Director, Stanford Institute for Human-Centered AI\n\n    From The Worlds I See: Curiosity, Exploration, and Discovery at the Dawn of AI [1]\n\nThe last several decades have witnessed a growing mistrust in science among both policy makers and the public at large on an unprecedented scale [2]. The reasons for this trend appear to be many and varied, including a lack of understanding about how science actually operates, partly at least due to an absence of participatory educational opportunities and direct engagement in meaningful science activities [3]. This, in turn, has been linked with poor self-ratings of scientific literacy among school-aged adolescents and adults alike [3]. A general confusion about what the public should reasonably expect from research in terms of scientific veracity or \u201ctruth\u201d has been an additional contributor to the public\u2019s skepticism about science. These problems have been amplified to a significant extent by social media, which has often worked, either intentionally or unintentionally, to confuse or obfuscate the truth [4]. Unfortunately, such efforts arguably have been abetted by scientific institutions themselves as well as scientific journal outlets which, in their haste to grab the day\u2019s headlines, have at times stripped scientific results of their complexity, nuance, and context; or, shockingly, filled untold numbers of journals with \u201cfake science\u201d [5]. Well-documented historical injustices also have contributed to a lack of trust in academic and scientific institutions, particularly among communities of color. For example, the US Public Health Service Untreated Syphilis Study at Tuskegee has generated mistrust in health care institutions and research for generations [6]. More recently, the University of Arizona was found guilty of using DNA samples from the Havasupai Tribe for research without their consent [7]. Recent controversies and public health crises (eg, the COVID-19 pandemic) also have given rise to increased questioning of public health authorities and have sown doubts regarding scientific validity and reliability, which have exacerbated feelings of mistrust.\n\nThis alarming trend of mistrust in science threatens public health efforts in multiple ways, which include the following recent examples: (1) misinformation concerning vaccines, including outright dismissal of the extensive multigenerational evidence base supporting the development and use of vaccines to prevent a myriad of dangerous and at times fatal diseases that have threatened the public\u2019s health; (2) skepticism surrounding the wide-ranging, multidisciplinary evidence base establishing the considerable effects of climate change that threaten the health of the planet and all of its living inhabitants; and (3) the growing distrust of health care systems as well as pharmaceutical companies (ie, \u201cbig Pharma\u201d), which has become especially acute among marginalized groups, including minoritized and under-resourced communities [8].\n\nThe mistrust of science coincides with other pernicious societal trends reflecting disconnection and skepticism in other facets of daily life. These include growing concerns in the health and mental health fields around the current levels of civic disconnectedness and community disengagement among significant sections of the population. Recent data indicate, for example, that civic participation, social engagement, and community connection among segments of today\u2019s youth and young adults are declining, with this trend having been worsened by the COVID-19 pandemic [9].\n\nThe confluence of these trends with the emergence of an often-bewildering pace of advances in the worldwide IT sector has served to exacerbate feelings of confusion and mistrust among broad segments of the population. This has included, in particular, the unexpectedly disruptive force of the current artificial intelligence (AI) revolution across all sectors, including health care, education, and research. Threats regarding the spread of misinformation, increasing systematic biases against already marginalized populations, data privacy issues, and potential job displacement are among the leading concerns of the public, in addition to other impacts that the widespread acceptance and use of AI might have on various segments of society, from individuals through governments and policy makers [10].\n\nThe above issues have led to the following questions: (1) how can science in general be made more accessible to the public in ways that can reduce confusion and mistrust and increase the meaningfulness of scientific inquiry to directly benefit individuals and their communities, and (2) how can the potential of AI be harnessed to bolster the public\u2019s engagement in public health science while mitigating the distrust and confusion about both research and AI itself?\nIncreasing Public Participation in Scientific Research\n\nPublic participation in science research (PPSR) is one way researchers have been addressing the increasing mistrust among decision makers and the public toward science. A growing number of studies have included PPSR methods, such as citizen science, that have utilized educational outreach efforts to increase public knowledge and awareness of scientific principles and best practices [11]. Important, systematic efforts have been employed to actively involve a greater number and variety of community members in the scientific process [12]. Such participatory research paradigms can have substantial positive impacts for increasing transparency, knowledge, and trust in scientific inquiry, particularly when they involve generating actionable data of direct relevance to those involved [13].\n\nWithin the broader umbrella of PPSR frameworks, citizen science\u2014generally defined as involving lay persons in the research process to advance science\u2014is an increasingly popular approach to engage community members in research activities [14]. A strength behind citizen science is its underlying principle that scientific inquiry can often benefit from including diverse members of the community from varying educational, occupational, social, and cultural backgrounds. Various forms of citizen science have occurred over several centuries and have involved diverse fields, including the life, environmental, health, social, and behavioral sciences [15]. Citizen science can directly benefit research by providing extra pairs of \u201chelping hands\u201d in the data collection and problem-solving aspects of science [14]. Beyond democratizing data acquisition, citizen scientists also can contribute to the fuller research process, including problem definition, data interpretation and prioritization, data-driven solution generation, and results dissemination [16-18]. This more fully participatory \u201cby the people\u201d form of citizen science can advance scientific inquiry as well as promote meaningful knowledge and solutions for the local communities that are involved [13,16,17].\n\nAn example of this type of citizen science in the public health arena is the technology-enabled \u201cOur Voice\u201d Global Citizen Science Research Initiative [19], where residents from diverse and often under-resourced communities learn how to partner with researchers and community organizations in collecting and interpreting aggregated and anonymized contextual data (eg, photos, text, and audio). These data identify features of residents\u2019 local environments that help or hinder their health [16,17]. They then learn how to effectively communicate their data to decision makers and work with them to activate health-benefiting changes in their local environments [16,17]. Over nearly a decade, the multi-generational \u201cOur Voice\u201d Initiative has produced demonstrable community-driven physical and social environmental impacts across 100+ projects involving over 25 countries spanning 6 continents [16,17].\nLeveraging the Potential of AI to Promote More Powerful Citizen Science for Advancing Public Health\n\nWhile the current focus of health-oriented AI applications has been primarily at the individual patient level, the thoughtful and strategic application of AI at the community level offers potentially powerful tools to augment participatory science activities across the fuller research process. At the same time, it is important that both researchers and participants recognize the potential risks of AI and are committed to implementing multilayered mitigation tactics aimed at addressing them (see Table 1, Figure 1, and the subsequent section focused on risk mitigation).\nTable 1. Examples of potential artificial intelligence (AI) uses within community-engaged public health citizen science research, along with potential risks and risk mitigation strategies.\nPotential use of AI within community-engaged research \tPotential risks \tRisk mitigation strategies\nConversational LLMsa\n\n(ChatGPT or similar) for onboarding participants, offering personalized guidance on engaging with technology, and asking thought-provoking questions \t\n\n    Biased or culturally insensitive conversations emerge\n\n    AI \u201challucinations\u201d where factually inaccurate commentary is made\n\n\n\t\n\n    Dedicated time spent in prompt engineering to determine language best used to minimize these biases in this context, and then shared as best practices to the public\n\n    Public education on AI, the training data that were used, and discussion of shortcomings\n\n\nText-to-image Generative AI tools\n\n(DALL-E, Midjourney, or similar) for helping the community visualize their data (eg, turning text descriptions into relevant images) \t\n\n    Biased or culturally insensitive pictures generated and shared\n\n    Impossible or impractical to execute ideas presented\n\n\n\t\n\n    Human (expert) review and gatekeeping before images shared broadly to the public\n\n    Prompt engineering and similar efforts aimed at community data collection are shared with participants in advance to enhance the potential relevance and feasibility of solutions\n\n\nData Mining (Descriptive Analytics)\n\nfor analyzing macro- and microlevel data, generating integrated data reports, visualizations, etc. \t\n\n    Inaccuracies or AI hallucinations injected into the dataset\n\n    Loss of control, research rigor, and cognitive competence by scientists who defer too much to AI\n\n\n\t\n\n    Intentional efforts made to feed AI inclusive and community representative data\n\n    Recursive AI use: feed output back to AI to check for inaccuracies\n\n    Require scientists to review all data generated for accuracy and meet field standards for scientific literacy or competence\n\n\nData Mining (Predictive Analytics)\n\nfor reviewing large datasets, providing data aggregation reports, and generating visual aids to help the community interpret data \t\n\n    Data presented may result in wrong conclusions, resulting in further inequities\n\n    Loss of control, research rigor, and cognitive competence by scientists who defer too much to AI\n\n\n\t\n\n    Human (expert) review and governance of all generated findings\n\n    Recursive AI use: feed output back to AI to check for inaccuracies\n\n    Require scientists to review all data and methods for accuracy and meet field standards for scientific literacy or competence\n\n    Empirical testing of AI to determine when it helps or hurts scientific skills and competencies\n\n\nOpen in a new tab\na\n\nLLM: large language model\nFigure 1. Artificial intelligence (AI) integration and risk mitigation strategies for participatory action citizen science: example of \u201cOur Voice\u201d Method and workflow. LLM: large language model; OV: Our Voice.\n\nFigure 1.\nOpen in a new tab\n\nUsing the \u201cOur Voice\u201d multistep citizen science method as an example, potentially valuable AI applications can occur at each step (see Figure 1). The steps include resident-engaged data collection using a multilingual mobile app (\u201cDiscover\u201d step); facilitated analysis, discussion, and prioritization of relevant local issues (\u201cDiscussion\u201d step); leveraging of visualization technologies to bring potential solutions into clearer focus (\u201cImagine\u201d step); communicating relevant community issues and brainstorming feasible solutions with local decision makers (\u201cActivate\u201d step); and continued partnering with stakeholders in bringing action plans to fruition (\u201cChange\u201d step). In addition to these integral steps, the above \u201cOur Voice\u201d method has been supplemented at times with an increasingly proactive and thoughtful approach to engage the community prior to embarking on citizen science activities, as well as the thoughtful dissemination of findings and insights to researchers, decision makers, and the public (a \u201cShare\u201d step). The careful integration of relevant AI applications into these different citizen science processes may assist in supplementing and enriching the different step outputs, as well as helping to address at least some of the challenges with public trust, given the active role that community members play in this type of participatory science.\n\nSome examples of potentially relevant AI tools that can be explored are given below for each step.\nDiscover (Data Collection) Step\n\nA challenge to address in the discover (data collection) step is that the inclusion of AI in this step should not supersede the real, on-the-ground data collected by local citizen scientists. Any additional data presented by the AI at this step is intended to be an augmentation that goes through human review before it is included in project data capture.\n\nConversational large language models (LLMs) can be employed in a strategic and transparent way to personally guide the use of citizen science data collection apps such as the \u201cOur Voice Discovery Tool\u201d app, along with \u201creal-time\u201d dynamic prompts to more fully engage residents as they go through their data collection walks. In addition, utilizing computer vision, hearing, and other \u201creal-world\u201d perceptual sensing tools (eg, smell) may help to produce more robust and comprehensive data capture and classifications to augment the contextually focused citizen science data [20]. The goal of using such sensing tools along with LLMs would be to enrich citizen scientists\u2019 data collection activities to produce more nuanced and detailed data to analyze and combine with other relevant data sources (eg, geographic information systems and social network models).\nDiscuss Step\n\nA challenge to address in the discuss step is that AI should not absolve researchers and participants from the task of ensuring analytical accuracy and rigor, nor replace efforts in interpreting the data and gleaning insights. As AI is known at times to experience \u201challucinations\u201d and commit errors when it comes to data analysis and interpretation, whatever is generated by it should be seen as a first-pass draft of something that helps researchers and community members enrich their own interpretations and iterations.\n\nChatGPT and similar conversational LLMs can be engaged during community meetings to support residents\u2019 group discussions during data interpretation and solution-building activities. For example, LLMs may be able to support thoughtful community-level discussion and advocacy, not as an omniscient \u201cblack box\u201d but as an attentive community-level support system and Socratic thinking aide. Rather than attempting to \u201creplace\u201d community members\u2019 perspectives and lived experiences, LLMs may be employed to play the role of \u201cdevil\u2019s advocate\u201d in a more neutral way, to help residents better understand the concerns of marginalized groups as well as policy makers. LLMs also may allow participants to better assess the feasibility of their data-driven ideas for positive change by supplementing knowledge or experience gaps that the average citizen scientist may have (eg, \u201cConsidering the financial constraints of X and timeframe to solve this issue by Y, which of these 5 solutions are the most feasible to address \u2026..?\u201d). In presenting participants with more detailed background information regarding the implementation of different data-driven solutions or strategies, residents can be further informed about the potential complexities that come with improving their communities. AI also could be leveraged to generate and describe multilevel insights by combining diverse sources of data, from citizen scientist\u2013generated microscale data that capture local contexts and individual-level biosensing outputs (eg, heart rate and physiological stress responses) through macroscale population-based social determinants and health data. This, in turn, could result in the development of interactive maps from such mixed-methods data sources that arguably could foster faster insights and public health responses from policy makers. For example, the initial efforts to visually combine citizen scientist\u2013generated microscale data describing residents\u2019 neighborhood-lived experiences with macroscale epidemiological data about their larger environmental contexts have yielded richer results than would have been obtained from either data source alone [21]. Leveraging AI in this manner to assist with combining and visualizing different forms of data could actually free up researchers and citizen scientists to engage in higher-order thinking and analysis that is required for creatively addressing some of society\u2019s most pressing issues. For instance, in California, low participation in community-supported public health initiatives that provide opportunities for affordable healthy food access is often driven by diverse factors that can vary by locale. The multifactorial issues driving low program uptake often are challenging for researchers, governmental agencies, and community-based organizations to understand sufficiently to be able to intervene effectively. It is possible that AI tools could help by aiding the visualization of how microlevel \u201clived experience\u201d data vary with respect to macrolevel contextual data. Such multilevel visualizations would allow researchers and community partners to spend more of their time understanding and solving the problem, as opposed to gathering and synthesizing relevant data to describe the problem.\nImagine Step\n\nA challenge to address in the imagine step is that AI should not have free reign in determining what the best solutions for the community are. Using culturally tailored inputs, AI\u2019s creativity can be used as a supplemental aide to the collective community\u2019s brainstorming while not superseding it.\n\nSeveral AI tools may be useful in helping residents, decision makers, and researchers better imagine what scientifically generated health-enhancing changes can actually look like in their own communities and environments (eg, through generative AI text-to-image tools such as DALL-E and Midjourney). For example, Stanford\u2019s Center on Human-Centered Artificial Intelligence awarded a seed grant to \u201cOur Voice\u201d that will allow citizen scientists to take images collected during local \u201cdiscovery walks\u201d and transform them into reimagined futures through such generative AI tools (eg, an image of an unsafe intersection to get to school could be \u201cmorphed\u201d into images of different solutions such as a crosswalk, pedestrian bridge, etc). The early testing of this form of AI with school children living in the El Poz\u00f3n neighborhood of Cartagena, Colombia\u2014where the majority of inhabitants live below the poverty line and lack access to essential services\u2014is showing how the thoughtful, culturally tailored use of text-to-image AI tools can generate meaningful and actionable solutions to local environmental problems (eg, stagnant water and uncollected garbage). These rapid visual renderings could in turn lead to enhanced and richer discussions of trade-offs and foster new ideas among community members and researchers.\nActivate and Change Steps\n\nA challenge to address in the activate and change steps is that, as noted above, an optimal goal of AI use is to supplement and enrich such conversations, as opposed to driving them. Sharing the above types of visualization tools and information with local decision makers may help to jump-start relevant solution-building efforts. Generative AI could be used to aid in the creation of presentation materials, help community members role-play conversations with local decision makers in preparation for scheduled meetings with them, and identify issues and suggest modifications to the action plan created during the community meetings.\nShare Step\n\nA challenge to address in the share step is that it is recommended that researchers avoid risking diminished scientific rigor and accuracy through outsourcing major data interpretation to AI. As noted earlier, people are in the best position to fully understand and evaluate what the data mean, including, in this case, the citizen scientists who have collected those data.\n\nMachine learning tools also can be used to aid researchers in the aggregation of data across projects and expedite their ability to glean useful insights across different citizen science projects and research groups.\n\nIn addition to the above types of citizen science-oriented strategies, through utilizing AI-generated virtual reality simulations, citizen scientists along with other community members can experience physical, cultural, and social situations that they might not otherwise encounter in their daily lives [22]. Such AI-generated virtual reality simulations also can provide community members and decision makers with hands-on opportunities to interact with virtual characters representing differing cultural backgrounds that may lead to increased cultural sensitivity [22]. These AI-driven virtual or simulated environments can additionally allow community members to try out citizen science data gathering and similar tools before real-world use [20].\nAdditional Recommendations on Mitigating Potential Risks of AI\n\nAmidst the potentially promising uses of AI for the public health and citizen science fields noted above, including its potential to expand the breadth and utility of the data being collected and interpreted, a number of ethical challenges and concerns have been raised, some of which have been touched on earlier and in other articles [23]. These include the different types of risks, as described in this paragraph. AI could diminish, distort, or replace data being collected in the field with output that is less accurate (ie, AI \u201challucinations\u201d) and less representative of community member experiences and responses. AI output may be based on information and sources that are not culturally relevant or appropriate for a given community or context. Potential challenges emerge when AI is presented with contrasting ideas from citizen scientists, researchers, and other stakeholders and autonomously makes prioritization choices among them. The introduction of AI tools into the public health research process could actually serve to increase the \u201cdepersonalization\u201d of the research process, leading to a greater rather than a lower distrust of science. Finally, major concerns have been raised that through potentially oversimplifying and directing aspects of the scientific process, LLMs and similar AI tools could significantly diminish scientists\u2019 data processing skills and cognitive competencies.\n\nThe publicly available use of ChatGPT and similar generative AI tools as \u201cshort cuts\u201d for increasing time efficiencies at the potential expense of thought and deliberation has served to heighten many of these concerns.\n\nIn response to such threats, some potential solutions have begun to emerge (see Table 1), as described below.\nThoughtfulness and Transparency\n\nA potential solution is being thoughtful and transparent in determining when IA (information augmentation to support human intelligence) versus AI (artificial intelligence, which is often used as a replacement for some human activities) is best suited. For example, in places where the radius for impact is large and missteps would be difficult to rectify or could cause grave harm, AI, which to date generally does not have community participation or checks for bias mitigation, ought to be used with great caution. In such instances, using technology instead to aggregate and synthesize data findings, and leaving the interpretation of those findings to people, could be wiser.\n\nA mitigation example could be the data collection of citizen scientists\u2019 lived experiences in the context of community determinants of health that could be synthesized to share summary statistics, generate heat maps, or word clouds; however, any interpretation of their data, along with solution-building and implementation, would not be outsourced to AI without human supervision and community-level interpretations and buy-in.\nEmploying Explainable AI Concepts and Strategies\n\nAnother potential solution is the use of explainable AI (XAI) that involves processes and methods that allow human users to understand and better trust the results and output created by machine learning and similar algorithms. It can be used to describe an AI model, its expected uses and impacts, and potential biases (eg, based on sex or race).\n\nA mitigation example is the use of a set of vetted chat prompts and outlined best practices that could be provided to users (\u201cprompt engineering\u201d), instead of assuming that the results of ChatGPT are correct and accurate. These best practices could include examples of wording to enter into ChatGPT to improve results and ideally catch AI \u201challucinations.\u201d Here is one such example: \u201cFor any and all responses, end each response with a bulleted list that includes (1) any assumptions you are making, (2) citations of any sources you have used to determine the response to my prompt, and (3) any biases or concerns you want to review if you had access to unlimited data or personnel.\u201d In addition, the responses generated by the AI system can be fed back to itself with the prompt \u201cCheck this response for any factual inaccuracies or state anything you cannot back up with reputable sources.\u201d\nLaunching Active Educational and Outreach Initiatives\n\nThere are growing concerns related to the potential of AI, including generative AI, to promote biased results and intensify health inequities through the lack of diverse data that are representative of different societal groups. Therefore, it is important to launch active educational and outreach initiatives to better inform the public across all walks of life about AI, its uses, ethical implications, and the precautions about which people should be aware. Educational efforts aimed specifically at diverse communities and populations may help to increase transparency concerning both the promise and limitations of this emerging field. It also may help ensure that key community norms and values are taken into account [24]. Such outreach-based multidisciplinary and community-driven educational efforts tailored to the needs of different populations may additionally help to empower currently under-represented groups to actively participate in data collection and information sharing to help mitigate such biases [24]. Involving community members in the development of AI methodologies from the beginning is important to ensure transparency and reduce mistrust among participants [24]. While such proactive educational efforts have been focused primarily on health care, they could benefit public health research and activities as well.\n\nA mitigation example is described here. Zainab Garba-Sani and colleagues have developed the A.C.C.E.S.S. AI model, which lays a framework for involving communities in the AI-rollout process as follows: A = \u201cAffirm your aims,\u201d C = \u201cConsider your communities,\u201d C = \u201cCultivate your conversations,\u201d E = \u201cEmbrace your essentials,\u201d S = \u201cSpecify your scope,\u201d and S = \u201cScrutinize your spaces\u201d [24]. Through training sessions and workshops with diverse groups, A.C.C.E.S.S. serves the dual purpose of not only educating people about AI and its potential applications but also gathering their input on how AI should be thoughtfully designed for their unique contexts. Another example of such an initiative is the nonprofit \u201cAI4ALL\u201d movement that aims to advance an increasingly human-centered, inclusive AI discipline [25]. Through proactive participatory approaches such as these, we can begin to demystify AI and ensure that diverse communities are brought to the table when implementing AI tools.\nIncreasing Efforts to Improve Data Upon Which AI is Modeled and Trained\n\nAs AI is merely holding up a mirror to the society or data upon which it is trained, the biases inherent in AI responses are likely due to the missing perspectives and incomplete data upon which it was built. Leveraging collaborations across institutions, social or civic interest groups, and diverse communities to improve the training data should help AI become more aware of differing perspectives and hopefully reduce if not completely minimize the bias. Outreach-based multidisciplinary and community-driven educational efforts as described below that are tailored to the needs of different populations may additionally help to empower currently under-represented groups to actively participate in data collection and information sharing to help mitigate such biases [24].\n\nA mitigation example is the need for clear guidelines and incentives from scientific organizations, universities, journals, and granting organizations (eg, specific grant announcements from the NIH in this area) concerning expanding the population representativeness of the datasets upon which AI is based; this can send a clear message regarding the importance of this issue to the field as well as society at large.\nSetting AI-Specific Ethical Standards and Having Expected AI-Influenced Outputs Verified by Experts\n\nIt is important to set AI-specific ethical standards across universities, other research organizations, scientific outlets, and funding sources that include the ethics review of study methods as well as have the expected AI-influenced outputs verified by experts trained in the relevant ethics fields. Publishers of scientific journals, books, and other scientific communication channels should be encouraged to provide specific guidelines related to the publication of research investigations that include AI. Demanding transparency of AI use in scientific research more generally is recommended, as a growing collection of policy makers, technology developers, and scientific organizations are currently doing. Setting up appropriate \u201cguardrails\u201d prior to AI use is similarly important to help ensure that flawed, offensive, or inaccurate information does not unexpectedly find its way into AI-driven conversations or other outputs.\n\nA mitigation example is described here. As part of institutional review board policies and activities, some grant-making organizations have included, in addition to the review of a grant proposal\u2019s scientific merit, a separate ethics review involving experts in ethics and similar fields to identify areas of potential ethical concern and methods for the mitigation of such concerns. An example is the Stanford Human-Centered Artificial Intelligence Center\u2019s process of including a separate ethics review of AI grant proposals to help ensure that appropriate AI-relevant guardrails are in place prior to funding.\nRegulating Transparent Data Ownership and Use\n\nIt is important to regulate transparent data ownership and use to ensure that access to citizen science data is not limited by commercial interests [20]; this helps to ensure that AI tools and resources are available to everyone, which can democratize its use and diminish public suspicion and skepticism. For example, many users of ChatGPT and similar platforms may not understand that their data currently may be sent to the parent company OpenAI to subsequently power future AI learning, and then be ultimately used by unnamed sources for a variety of undisclosed purposes.\n\nA mitigation example is that, instead of relying on public GPTs whose data ownership and use are ambiguous, the Stanford School of Medicine and other academic institutions have developed their own custom GPT that ensure data security, HIPAA compliance, and similar outcomes. Additional AI resources that are being developed at Stanford include a user-friendly \u201cAI Playground\u201d platform, built on open-source technologies, that allows the Stanford community to try out various AI models and tools as well as compare the utility of different tools in a head-to-head fashion.\nHuman Governance and Oversight Over AI Output\n\nIt is imperative when undertaking community-engaged forms of research that scientists work to ensure that AI-generated contributions to the research endeavor do not supersede or otherwise hamper the credibility of the contributions from community members and their representatives. While AI tools are often used to obtain meaning from large datasets, in the participatory public health research field, it is typically the residents themselves who can best provide meaning and context to the data being collected and interpreted.\n\nA mitigation example is that the addition of community advisory experts, panels, and similar oversight bodies can help ensure that the use of AI enriches but does not overshadow either the scientific process itself or scientists and the public\u2019s participation in that process. It will be particularly valuable to include the expertise of ethicists familiar with AI who can identify potential areas of concern and help build appropriate safeguards.\nEnsuring That Scientific Competencies are Enhanced Rather Than Diminished as a Consequence of the AI \u201cRevolution\u201d\n\nWith the rapid expansion and ease of use of ChatGPT and other LLM tools across a range of scientific and educational fields, there have been growing concerns related to the detrimental effects that the overuse of such tools can have on current and future generations of scientists and the public. These concerns include the real danger that regular substitution of LLM-generated written and oral communication in science, as well as across other facets of life, could significantly diminish cognitive competencies and the creative and innovative thinking that is the foundation of the scientific process itself. It is clear, at this early stage of generative AI use in participatory science as well as in other scientific areas, that carefully created guidelines for AI usage in all aspects of scientific education and training should be developed and put into place to ensure LLMs and other AI tools support, rather than replace, the facilitation and participation of community-engaged research endeavors.\n\nA mitigation example is described here. A year-long deliberative process by Stanford University\u2019s Department of Epidemiology & Population Health has resulted in a clear set of early principles and guidelines for the use of generative AI tools in one of its major education programs. The guidelines have helped to diminish ambiguity among students and faculty while reinforcing the importance of human-centered educational activities in growing the cognitive competencies of vital importance to the advancement of science. In addition to clear guidelines for AI use and requirements that scientists at all levels of training and experience review their data and methods for accuracy, other suggestions include the further development of field-specific scientific standards for scientific literacy and competence independent of AI usage.\n\nIt is also important to ensure that scientific data collection and analysis activities themselves are not in some way diminished or curtailed through overdependence on AI tools. As noted earlier, the judicious use of certain AI tools in the participatory science area may help to enrich and expand the insights and impacts gained through participation by residents, decision makers, and scientists working together. However, it is critical that such AI tools undergo thorough empirical testing to determine when, how, and with whom they can enhance rather than impede scientific knowledge and insights. As one example, the \u201cOur Voice\u201d research team is conducting initial experiments to better determine how the use of \u201ctext-to-image\u201d generative AI may affect the ability of citizen scientists to better visualize and understand the proposed health-promoting environmental changes drawn from their data. Among the populations for which such tools are being systematically tested are older US women and school children living in the El Poz\u00f3n neighborhood of Cartagena, Colombia, which was highlighted earlier. In a second example, a recent \u201cOur Voice\u201d citizen science project conducted in Bogot\u00e1, Colombia has illustrated how resident-collected data that were augmented via virtual reality tools can ignite compelling discussions and solution building among participants, scientists, and local stakeholders [22].\n\nThe multidimensional mixed-methods data collection methods, sources, and analyses required by the types of participatory scientific methods described in this Viewpoint also may serve as a means for preventing the diminution of cognitive competencies. For example, we have found that the increased complexity of the multilevel, mixed-methods data acquired when microscale (eg, citizen scientists\u2019 \u201clived experiences\u201d) and macroscale data sources are integrated requires an increased interdisciplinary understanding of both these different forms of data and more intricate and multifaceted data analysis methods, which can serve to enhance cognitive competencies [21].\nDiscussion and Conclusions\n\nCitizen science has been shown to be effective in positively engaging diverse groups of community members in meaningful, action-oriented research [17]. Such participatory methods can help to lessen both mistrust in science and civic disengagement, which are trends that threaten to impair advances in public health. Can the judicious applications of various AI tools serve to amplify the potential of participatory science for reducing these trends while broadening meaningful scientific advances in public health? Given that it is clear that the AI \u201cgenie\u201d is out of the bottle and will likely have substantial impacts across virtually all aspects of science, it is critical that we meet the AI challenge head on. The inevitable integration of AI into participatory research methods must be thoughtfully managed in order to amplify, and not replace, the collective documentation of human lived experiences, and to ensure that the applications of such data to affect change truly reflect the priorities of local communities. We believe that the time is ripe to systematically evaluate the potential of AI beyond current individual-level applications by exploring its utility as a community aid for advancing public health. At the same time, it is imperative that we continually keep in mind the potential risks accompanying its use, especially among underserved, under-resourced communities. We call on the research community to consider such challenges proactively and empirically over the coming years, finding innovative ways to mitigate the risks while testing the impacts of AI on trust in science, civic engagement, knowledge advancement, and community-driven change.\nAcknowledgments\n\nThe authors thank Ann Banchoff, MSW, MPH and Steven Lovett, PhD for their valuable input related to this manuscript. We also thank Eduardo De La Vega Sr, PhD for his innovative early community-engaged research activities in Colombia using generative large language models, and Arjan Walia, MS for his leadership in the initial systematic evaluation of generative artificial intelligence models in community-engaged research with older US women. Dr. King received partial support from US Public Health Services grants 5R01AG07149002 (King) and 1R44AG071211 (M Fauci) from the National Institute on Aging. King, Doueiri, and Kaulberg received partial support from a seed grant provided by the Stanford Institute for Human-Centered Artificial Intelligence at Stanford University. The authors declare no potential conflicts of interest with respect to the research, authorship, or publication of this article. No copyrighted material, surveys, instruments, or tools are included in this manuscript.\nAbbreviations\n\nAI\n\n    artificial intelligence\nLLM\n\n    large language model\nPPSR\n\n    public participation in science research\n\nFootnotes\n\nConflicts of Interest: None declared.\nReferences\n\n    1.The Worlds I See: Curiosity, Exploration, and Discovery at the Dawn of AI. Macmillan Publishers; 2024. p. 4. [Google Scholar]\n    2.Kennedy B, Tyson A. Americans\u2019 Trust in Scientists, Positive Views of Science Continue to Decline. Pew Research Center; 2023. [14-11-2023]. https://www.pewresearch.org/science/2022/02/15/americans-trust-in-scientists-other-groups-declines URL. Accessed. [Google Scholar]\n    3.Achterberg P, de Koster W, van der Waal J. A science confidence gap: Education, trust in scientific methods, and trust in scientific institutions in the United States, 2014. Public Underst Sci. 2017 Aug;26(6):704\u2013720. doi: 10.1177/0963662515617367. doi. Medline. [DOI] [PubMed] [Google Scholar]\n    4.Epstein Z, Sirlin N, Arechar A, Pennycook G, Rand D. The social media context interferes with truth discernment. Sci Adv. 2023 Mar 3;9(9):eabo6169. doi: 10.1126/sciadv.abo6169. doi. Medline. [DOI] [PMC free article] [PubMed] [Google Scholar]\n    5.Nasr N. Overcoming the discourse of science mistrust: how science education can be used to develop competent consumers and communicators of science information. Cult Stud Sci Educ. 2021;16(2):345\u2013356. doi: 10.1007/s11422-021-10064-6. doi. Medline. [DOI] [PMC free article] [PubMed] [Google Scholar]\n    6.Alsan M, Wanamaker M. Tuskegee and the health of black men. Q J Econ. 2018 Feb;133(1):407\u2013455. doi: 10.1093/qje/qjx029. doi. Medline. [DOI] [PMC free article] [PubMed] [Google Scholar]\n    7.Garrison NA. Genomic justice for native Americans: impact of the Havasupai case on genetic research. Sci Technol Human Values. 2013;38(2):201\u2013223. doi: 10.1177/0162243912470009. doi. Medline. [DOI] [PMC free article] [PubMed] [Google Scholar]\n    8.Bazargan M, Cobb S, Assari S. Discrimination and medical mistrust in a racially and ethnically diverse sample of California adults. Ann Fam Med. 2021;19(1):4\u201315. doi: 10.1370/afm.2632. doi. Medline. [DOI] [PMC free article] [PubMed] [Google Scholar]\n    9.Kannan VD, Veazie PJ. US trends in social isolation, social engagement, and companionship \u23af nationally and by age, sex, race/ethnicity, family income, and work hours, 2003-2020. SSM Popul Health. 2023 Mar;21:101331. doi: 10.1016/j.ssmph.2022.101331. doi. Medline. [DOI] [PMC free article] [PubMed] [Google Scholar]\n    10.Byrne M. The disruptive impacts of next generation generative artificial intelligence. Comput Inform Nurs. 2023 Jul 1;41(7):479\u2013481. doi: 10.1097/CIN.0000000000001044. doi. Medline. [DOI] [PubMed] [Google Scholar]\n    11.Haywood BK, Besley JC. Education, outreach, and inclusive engagement: Towards integrated indicators of successful program outcomes in participatory science. Public Underst Sci. 2014 Jan;23(1):92\u2013106. doi: 10.1177/0963662513494560. doi. Medline. [DOI] [PubMed] [Google Scholar]\n    12.Mintz E, Couch J. Biomedical citizen science at the National Institutes of Health. Citiz Sci. 2022 Dec 15;7(1):16651505. doi: 10.5334/cstp.543. doi. [DOI] [Google Scholar]\n    13.Skarlatidou A, Haklay M, Hoyte S, van Oudheusden M, Bishop IJ. How can bottom-up citizen science restore public trust in environmental governance and sciences? Recommendations from three case studies. Environ Sci Policy. 2024 Oct;160:103854. doi: 10.1016/j.envsci.2024.103854. doi. [DOI] [Google Scholar]\n    14.King AC, Winter SJ, Chrisinger BW, Hua J, Banchoff AW. Maximizing the promise of citizen science to advance health and prevent disease. Prev Med. 2019 Feb;119:44\u201347. doi: 10.1016/j.ypmed.2018.12.016. doi. Medline. [DOI] [PMC free article] [PubMed] [Google Scholar]\n    15.Allf BC, Cooper CB, Larson LR, et al. Citizen science as an ecosystem of engagement: implications for learning and broadening participation. Bioscience. 2022 Jul;72(7):651\u2013663. doi: 10.1093/biosci/biac035. doi. Medline. [DOI] [PMC free article] [PubMed] [Google Scholar]\n    16.King AC, King DK, Banchoff A, et al. Employing participatory citizen science methods to promote age-friendly environments worldwide. Int J Environ Res Public Health. 2020 Feb 27;17(5):1541. doi: 10.3390/ijerph17051541. doi. Medline. [DOI] [PMC free article] [PubMed] [Google Scholar]\n    17.King AC, Odunitan-Wayas FA, Chaudhury M, et al. Community-based approaches to reducing health inequities and fostering environmental justice through global youth-engaged citizen science. Int J Environ Res Public Health. 2021 Jan 21;18(3):892. doi: 10.3390/ijerph18030892. doi. Medline. [DOI] [PMC free article] [PubMed] [Google Scholar]\n    18.English PB, Richardson MJ, Garz\u00f3n-Galvis C. From crowdsourcing to extreme citizen science: participatory research for environmental health. Annu Rev Public Health. 2018 Apr 1;39:335\u2013350. doi: 10.1146/annurev-publhealth-040617-013702. doi. Medline. [DOI] [PubMed] [Google Scholar]\n    19.King AC. Our Voice Global Citizen Science Research Initiative. 2024. [27-01-2025]. https://ourvoice.stanford.edu URL. Accessed.\n    20.Ceccaroni L, Bibby J, Roger E, et al. Opportunities and risks for citizen science in the age of artificial intelligence. Citiz Sci. 2019 Nov 28;4(1):1\u201314. doi: 10.5334/cstp.241. doi. [DOI] [Google Scholar]\n    21.Soltani S, Hinman JA, Blanco-Velazquez I, et al. Bringing micro to the macro: how citizen science data enrich geospatial visualizations to advance health equity. J Maps. 2023;19(1):2216217. doi: 10.1080/17445647.2023.2216217. doi. Medline. [DOI] [PMC free article] [PubMed] [Google Scholar]\n    22.Guevara-Aladino P, Sarmiento OL, Rubio MA, et al. Urban care for unpaid caregivers: community voices in the care block program, in Bogot\u00e1, Colombia. J Urban Health. 2024 Dec;101(6):1113\u20131127. doi: 10.1007/s11524-024-00899-z. doi. Medline. [DOI] [PMC free article] [PubMed] [Google Scholar]\n    23.Hsu YC, Verma H, Mauri A, Nourbakhsh I, Bozzon A. Empowering local communities using artificial intelligence. Patterns (N Y) 2022 Mar 11;3(3):100449. doi: 10.1016/j.patter.2022.100449. doi. Medline. [DOI] [PMC free article] [PubMed] [Google Scholar]\n    24.Garba-Sani Z, Farincacci-Roberts C, Essien A. AI: A new framework for advancing health equity in health care AI. Health Aff. 2024 doi: 10.1377/forefront.20240424.369302. doi. [DOI] [Google Scholar]\n    25.Stanford University; [11-11-2024]. AI4ALL webpage.https://ai-4-all.org URL. Accessed. [Google Scholar]\n\n\n\n\n    Article\n    Open access\n    Published: 16 October 2025\n\nAutomated real-time assessment of intracranial hemorrhage detection AI using an ensembled monitoring model (EMM)\n\n    Zhongnan Fang, Andrew Johnston, Lina Y. Cheuy, Hye Sun Na, Magdalini Paschali, Camila Gonzalez, Bonnie A. Armstrong, Arogya Koirala, Derrick Laurel, Andrew Walker Campion, Michael Iv, Akshay S. Chaudhari & David B. Larson \n\nnpj Digital Medicine volume 8, Article number: 608 (2025) Cite this article\n\n    2317 Accesses\n\n    16 Altmetric\n\n    Metrics details\n\nAbstract\n\nArtificial intelligence (AI) tools for radiology are commonly unmonitored once deployed. The lack of real-time case-by-case assessments of AI prediction confidence requires users to independently distinguish between trustworthy and unreliable AI predictions, which increases cognitive burden, reduces productivity, and potentially leads to misdiagnoses. To address these challenges, we introduce Ensembled Monitoring Model (EMM), a framework inspired by clinical consensus practices using multiple expert reviews. Designed specifically for black-box commercial AI products, EMM operates independently without requiring access to internal AI components or intermediate outputs, while still providing robust confidence measurements. Using intracranial hemorrhage detection as our test case on a large, diverse dataset of 2919 studies, we demonstrate that EMM can successfully categorize confidence in the AI-generated prediction, suggest appropriate actions, and help physicians recognize low confidence scenarios, ultimately reducing cognitive burden. Importantly, we provide key technical considerations and best practices for successfully translating EMM into clinical settings.\nSimilar content being viewed by others\nA real-world demonstration of machine learning generalizability in the detection of intracranial hemorrhage on head computerized tomography\nArticle Open access 23 August 2021\nTesting the applicability and performance of Auto ML for potential applications in diagnostic neuroradiology\nArticle Open access 11 August 2022\nSynergizing advanced algorithm of explainable artificial intelligence with hybrid model for enhanced brain tumor detection in healthcare\nArticle Open access 01 July 2025\nIntroduction\n\nThe landscape of healthcare has rapidly evolved in recent years, with an exponential increase in FDA-cleared artificial intelligence (AI) software as medical devices, especially in radiology1. Despite the number of AI applications available, the clinical adoption of radiological AI tools has been slow due to safety concerns regarding potential increases in misdiagnosis, which can erode overall trust in AI systems2. Such inaccurate predictions force meticulous verification of each AI result to avoid cognitive pitfalls such as automation and confirmation biases2,3, ultimately adding to the user\u2019s cognitive workload rather than fulfilling AI\u2019s promise to enhance clinical efficiency4. These cognitive influences on clinical decision making, along with potential mismatches between expected and actual AI performance, indicate a clear need for real-time monitoring to inform physicians on a case-by-case basis about how confident they can be in each prediction. Such real-time monitoring alongside a physician\u2019s image interpretation also goes hand-in-hand with the latest guidance issued by the FDA focusing on total life-cycle management of AI tools, rather than the status-quo of pre-deployment validation5. However, there are currently limited guidelines or best practices for real-time monitoring to communicate reduced confidence in an AI model\u2019s prediction.\n\nCurrent monitoring of radiological AI devices is performed retrospectively based on concordance between AI model outputs and manual labels, which require laborious radiologist-led annotation6. Due to the resource-intensive nature of generating these labels, the vast majority of retrospective evaluations are limited to small data subsets, providing only a partial view of real-world performance7. While recent advances in large language models (LLMs) have shown promise in the analysis of clinical reports8,9,10, including automated extraction of diagnosis labels from radiology reports11,12,13, this solution remains retrospective. Moreover, with report-based monitoring, regardless of the extraction technique, the \u201cquality control\u201d mechanism for algorithm performance remains a manual task. An automated quality monitoring solution may help decrease the user\u2019s cognitive burden and provide additional objective information regarding the performance of the AI model, including performance drift.\n\nIn response to these limitations, various real-time monitoring techniques have been proposed, including methods that can directly predict model confidence using the same training dataset used to develop the AI model being monitored14,15,16,17,18,19. Common classes of confidence estimation rely on methods such as SoftMax probability calibration20,21,22, Bayesian neural networks23,24,25,26, and Monte Carlo dropout27,28. Deep ensemble approaches have also emerged to evaluate prediction reliability by utilizing groups of models derived from the same parent model with varying augmentations29,30,31,32,33. However, these methods require access to either the training dataset, model weights, or intermediate outputs, which is not practical when monitoring commercially available models. Since all FDA-cleared radiological AI models that are deployed clinically are black-box in nature, there currently exist no techniques to monitor such models in production in real time.\n\nThus, there remains a critical need for a real-time monitoring system to automatically characterize model confidence at the point-of-care (i.e., when the radiologists review the images and the black-box AI prediction in question). To address this need, we developed the Ensembled Monitoring Model (EMM) approach, which is inspired by clinical consensus practices, where individual opinions are validated through multiple expert reviews. EMM comprises multiple sub-models trained for an identical task and estimates model confidence in the black-box AI prediction based on the level of agreement seen between the sub-models and the black-box primary model. This approach enables prospective real-time case-by-case monitoring, without requiring ground-truth labels or access to internal AI model components, making it deployable for black-box systems. Here, we demonstrate the effectiveness of the EMM approach in characterizing the confidence of intracranial hemorrhage (ICH) detection AI systems (one FDA-cleared and one open-source) operating on head computed tomography (CT) imaging. In this clinically significant application requiring high reliability, we show how EMM can monitor AI model performance in real time and inform subsequent actions in cases flagged for decreased accuracy. The complementary use of a primary model with EMM can improve accuracy and user trust in the AI model, while potentially reducing the cognitive burden of interpreting ambiguous cases. We further investigate and provide key considerations for translating and implementing the EMM approach across different clinical scenarios.\nResults\nEnsembled monitoring model (EMM) overview\n\nEmulating how clinicians achieve group consensus through a group of experts, the EMM framework was developed to estimate consensus among a group of models. Here, we refer to the model being monitored as the \u201cprimary model\u201d. In this study, the EMM comprised five sub-models with diverse architectures trained for the identical task of detecting the presence of ICH (Fig. 1). Each sub-model within the EMM independently processed the same input to generate its own binary prediction (e.g., the input image is positive or negative for ICH), in parallel to the primary ICH detection model. Each of the five EMM outputs were compared to the primary model\u2019s output using unweighted vote counting to measure agreement in discrete 20% increments from 0% (no EMM sub-models agreed) to 100% (all five sub-models agreed). This level of agreement can translate into increased, similar, and reduced confidence levels in the primary output.\nFig. 1: Overview of the Ensembled Monitoring Model (EMM).\nfigure 1\n\nEach sub-model within the EMM is trained to perform the same task as the primary ICH detection model. The independent sub-model outputs are then used to compute the level of agreement between the primary ICH detection model and EMM, helping quantify confidence in the reference prediction and suggesting an appropriate subsequent action.\nFull size image\nEMM agreement levels are associated with different features\n\nTo identify the features most commonly associated with high EMM agreement, we visually examined all 2919 CT scans for two complementary primary models, an FDA-cleared model with higher specificity, precision and accuracy, and an open-source model34,35 with higher sensitivity (Supplementary Fig. 1).\n\nResults of the FDA-cleared primary model are shown in Fig. 2a, and the results of the open-source primary model are shown in Supplementary Fig. 2. The FDA-cleared primary model and EMM demonstrated 100% agreement and correct classifications in 1479 cases (51%, 632 ICH-positive, 847 ICH-negative), primarily in cases with obvious hemorrhage or clearly normal brain anatomy. EMM showed partial agreement with the FDA-cleared primary model in 848 cases (29%, 151 ICH-positive, 697 ICH-negative) when the FDA-cleared primary model was correct. EMM also showed partial agreement in 454 cases (16%, 415 ICH-positive, 39 ICH-negative) when the FDA-cleared primary model was incorrect. Visual examination revealed that the cases with partial agreement typically presented with subtle ICH or contained imaging features that mimicked hemorrhage (e.g., hyperdensity, such as calcification or tumor). These cases of partial agreement provide an opportunity for further radiologist review. Finally, in 138 cases (4%, 117 ICH-positive, 21 ICH-negative), EMM demonstrated 100% agreement with the FDA-cleared primary model, but EMM failed to detect that the FDA-cleared primary model\u2019s prediction was wrong. These cases predominantly involved either extremely subtle hemorrhages or CT features that strongly mimicked hemorrhage patterns, confusing both the FDA-cleared primary model and EMM.\nFig. 2: EMM agreement associated with different features.\nfigure 2\n\na Example cases for which EMM showed different levels of agreement with the FDA-cleared primary model. Cases with full EMM agreement typically showed clear presence or absence of ICH, while cases with partial agreement often displayed subtle ICH or features mimicking hemorrhage. b Quantitative analysis on the importance of features affecting EMM agreement with the FDA-cleared primary model in ICH-positive and ICH-negative cases. The normalized weight of importance for all features sums to 100%.\nFull size image\n\nWe then quantitatively examined which features affected EMM agreement using Shapley analysis36. This analysis was performed on a data subset (N\u2009=\u2009281) with a comprehensive set of features manually labeled by radiologists spanning multiple categories, including pathology, patient positioning, patient information, image acquisition, and reconstruction parameters. In ICH-positive cases, hemorrhage volume emerged as the dominant feature for high EMM agreement, with larger volumes strongly corresponding to higher agreement (Fig. 2b), as seen in our visual analysis. For ICH-negative cases, the predictive features for EMM agreement were more balanced. The top predictors for EMM agreement were brain volume, patient age, and image rotation. Some directional relationships between feature values and EMM agreement were also identified (Supplementary Fig. 2). For ICH-positive cases, high hemorrhage volume and multi-compartmental hemorrhages resulted in higher EMM agreement. In ICH-negative cases, the presence of features that mimicked hemorrhages led to lower EMM agreement.\nEMM enables confidence-based image review optimization\n\nThe level of EMM agreement with the primary ICH detection model and the resulting degree of confidence also enables radiologists to make different decisions on a case-by-case basis. By setting stratification thresholds (Fig. 3) based on EMM agreement levels that are higher than, similar to, or lower than the primary AI\u2019s baseline performance (Supplementary Fig. 3), primary predictions can be grouped into three categories, indicating scenarios where the radiologist may have increased, similar, or decreased confidence. This stratification allows radiologists to adjust their actions accordingly for each image read. For example, the primary model\u2019s prediction might not be used in cases with decreased confidence, and these cases should be reviewed following a radiologist\u2019s conventional image interpretation protocol. As we show in the following paragraph, such optimization may potentially improve radiologist efficiency and reduce cognitive load.\nFig. 3: An example EMM use case is stratifying cases into categories of increased, similar, or decreased confidence in the primary model predictions based on the level of EMM agreement.\nfigure 3\n\nThe stratification thresholds were selected by evaluating the primary model\u2019s performance at different levels of EMM agreement, specifically, those where performance was higher than, similar to, or lower than its baseline (Supplementary Fig. 3). This categorization enables radiologists to make tailored decisions based on the confidence level derived from the EMM agreement levels. For ICH-positive predictions, confidence was stratified using EMM agreement thresholds of 100% (increased), 60, 80% (similar), and 0, 20, 40% (decreased). For ICH-negative predictions, thresholds were 100% (increased), 20, 40, 60, 80% (similar), and 0% (decreased).\nFull size image\n\nFollowing the EMM thresholds and suggested actions outlined in Fig. 3, we then evaluated the overall accuracy of the primary model together with EMM for cases classified as increased, similar, and decreased confidence for the FDA-cleared primary model (Fig. 4a). This evaluation was also performed across three different prevalences of 30, 15, and 5%, which are close to the prevalences observed at our institution across emergency, in-patient, and out-patient settings. As expected, overall accuracy was highest for cases in which the primary model and EMM showed high agreement, and overall accuracy was lowest when EMM showed a lower agreement level with the primary model. This was observed for both ICH-positive and ICH-negative primary predictions and across all prevalence levels. Of the cases analyzed, most were classified as increased confidence based on EMM thresholds, followed by similar confidence, and lastly decreased confidence (Fig. 4b).\nFig. 4: EMM stratifies cases into different accuracy groups for the FDA-cleared primary model and enables customized clinical decision making.\nfigure 4\n\na Cases stratified by EMM agreement levels demonstrated increased (green), similar (yellow), or decreased (red) accuracies compared to the baseline accuracy of the primary model without EMM (gray). b Distribution (%) of cases classified as increased (green), similar (yellow), or decreased (red) confidence based on the EMM agreement thresholds. c For the cases in which EMM indicated decreased confidence, a more detailed radiologist review was called for. Cases flagged for decreased confidence, but for which the primary model\u2019s prediction was correct, were defined as false alarms. Substantial relative gains over baseline accuracy using only the primary model were observed across all prevalence levels for ICH-positive primary model predictions, outweighing the burden of false alarms. For ICH-negative primary model predictions, however, this favorable balance between relative accuracy gains and false alarm burden was only observed at 30% prevalence. *, **, ***, and NS indicate p < 0.05, <0.01, <0.001, and not significant, respectively.\nFull size image\n\nTo assess the practical value of the EMM suggested actions, we analyzed the relative gains of the model compared to the cognitive load and loss of trust associated with incorrect classifications. Among the cases flagged for decreased confidence, those for which the primary model\u2019s prediction remained correct despite low EMM agreement (and thus the decreased confidence classification) were considered false alarms. As shown in Fig. 4c, alerting radiologists to potentially incorrect positive outputs from the primary model enabled them to correct these cases, substantially improving relative accuracy and outweighing the false-alarm rate across all prevalence levels (relative accuracy improvements of 4.66, 11.28, and 38.57% versus false-alarm rates of 0.89, 0.45, and 0.14% at prevalence levels of 30, 15, and 5%, respectively). However, this net benefit was only observed for cases with ICH-negative primary model predictions at 30% prevalence (false-alarm rate of 1.05% versus relative accuracy improvement of 3.35%). At lower prevalence levels (15 and 5%), the already-high baseline accuracy of the primary model for ICH-negative cases (i.e., accuracy\u2009=\u20090.93 and 0.98, respectively) meant that the burden of false alarms (1.27 and 1.40%) did not exceed the relative accuracy gains (1.37 and 0.41%). Similar results were also observed for the open-source primary model across all prevalences (Supplementary Fig. 4).\nSub-model and data size considerations when training EMM\n\nTo enable broader application and adoptability, we conducted a comprehensive analysis of how three key factors influence EMM performance and assessed its data efficiency and generalizability: (i) amount of training data used: 100% of the dataset (N\u2009=\u200918,370), 50% of the dataset (N\u2009=\u20099185), 25% of the dataset (N\u2009=\u20094592), and 5% of the dataset (N\u2009=\u2009918), (ii) number of EMM sub-models (1\u20135), and (iii) EMM sub-model size in relation to training data volume. EMM performance was measured by its ability to detect errors made by the primary model using error detection sensitivity-PPV area under curve (ED-SPAUC) and specificity-NPV area under curve (ED-SNAUC) across prevalences, as these metrics consider the overall error detection performance regardless of the agreement level threshold applied.\nTraining data volume\n\nAs illustrated in Fig. 5a, EMM\u2019s ED-SPAUC for the FDA-cleared primary model generally decreased as the training data were reduced from 100 to 5% of the original dataset across all three prevalences. This suggested that EMM generally improves with increased training data volume, though the benefits begin to saturate after approximately 4,600 studies (i.e., 25% of data). This trend was also observed in the ED-SNAUC and the open-source primary model (Supplementary Fig. 5a).\nFig. 5: EMM performance for detecting errors made by the commercial primary model generally improved with increasing data volume and sub-model complexity.\nfigure 5\n\na Training data volume. b Number of sub-models. c Sub-model sizes. Error detection sensitivity-PPV area under curve (ED-SPAUC) and specificity-NPV area under curve (ED-SNAUC) were measured across prevalences; higher values are desirable for both. S-Net represents small sub-model networks for EMM and L-Net represents large sub-model networks for EMM. Similar results for the open-source primary model are shown in Supplementary Fig. 5.\nFull size image\nNumber of ensemble sub-models\n\nAs shown in Fig. 5b, EMM\u2019s ED-SPAUC increased as the number of sub-models increased from 1 to 4, before generally stabilizing at 5 across all three prevalence levels. Conversely, ED-SNAUC consistently improved as the number of models increased from 1 to 5, across all prevalences. Similarly, both error detection metrics showed consistent improvement as the number of networks increased for the open-source primary model (Supplementary Fig. 5b). These results suggest that EMM performance generally increases with more sub-models, with 4 or 5 sub-models serving as an effective starting point for future applications.\nEnsemble sub-model size and training data\n\nWe next investigated how combinations of EMM sub-model size and training data volume affected EMM\u2019s performance in monitoring the primary model. We examined four scenarios: (i) ensemble of small networks trained with 5% of the dataset (S-Net 5%-Data), (ii) ensemble of small networks trained with 100% of the dataset (S-Net 100%-Data), (iii) ensemble of large networks trained with 5% of the dataset (L-Net 5%-Data), and (iv) ensemble of large networks trained with 100% of the dataset (L-Net 100%-Data). As shown in Fig. 5c, EMM generally achieved the best ED-SPAUC and ED-SNAUC with large networks and 100% of the training data and worst performance with a large network and 5% of training data, suggesting that a larger training dataset could benefit EMM performance. In a 5% prevalence setting, an ensemble of small networks and 5% of the training data achieved the highest ED-SPAUC and ED-SNAUC values. Similar findings were also observed for the open-source primary model (Supplementary Fig. 5c).\n\nAdditionally, we analyzed EMM performance across gender, age and race groups and found discrepancies in some subgroups, potentially due to either underrepresentation in the EMM training data or the distribution mismatch between the EMM training data and our internal testing dataset for these subgroups (Supplementary Fig. 6).\n\nTaken together, these results provide insights into how the EMM approach can be developed and tailored for various real-time monitoring applications.\nDiscussion\n\nIn this paper, we introduce EMM, a framework that monitors black-box clinical AI systems in real-time without requiring manual labels or access to the primary model\u2019s internal components. Using an ensemble of independently trained sub-models that mirror the primary task, our framework measures confidence in AI predictions through agreement levels between the EMM sub-models and the primary model on a case-by-case basis. We also showed that the EMM agreement level can be used to stratify cases by confidence in the primary model\u2019s prediction and suggest a subsequent action. For example, reviewing cases where EMM showed decreased confidence led to substantial relative accuracy gains that outweighed the burden of false alarms. Taken together, these results show that EMM is a valuable tool that fills the critical gap in real-time, case-by-case monitoring for FDA-cleared black-box AI systems, which would otherwise remain unmonitored. Finally, we explored how EMM can be generalized for future applications and demonstrated how EMM performance varies with different amounts of training data, as well as the number and size of sub-models, providing insights into how EMM can be adapted for various resource settings.\n\nOur approach enables quantification of confidence through EMM agreement levels with the primary model\u2019s predictions. By applying appropriate thresholds to the level of agreement between the EMM and primary model, radiologists can differentiate between which predictions they can be confident in, therefore optimizing their attention allocation and cognitive load. For example, EMM indicated high confidence in over half of all cases interpreted in our test dataset. Notably, EMM also reliably identified cases of low confidence, allowing for focused review of these cases and greatly improving overall ICH detection accuracy. In our testing, EMM only failed alongside the primary model in a small percentage of cases (4%). These cases of both EMM and primary model being incorrect represent those with small ICH volumes or ICH-mimicking features.\n\nThe stratification of confidence levels based on the EMM agreement levels also enables radiologists to make tailored decisions for each case. The thresholds for defining the three accuracy groups in this study were established based on expert radiologist assessment and the primary model\u2019s performance at different EMM agreement levels (Supplementary Fig. 3), with separate analyses for ICH-positive and ICH-negative primary model predictions. The thresholds to indicate increased and decreased confidence were specifically designated so that the overall ICH detection accuracy would be significantly higher or lower, respectively, than that with only the primary model (baseline). However, suboptimal EMM agreement thresholds (resulting in too many cases categorized as decreased confidence) can create an unfavorable trade-off where the burden of further reviewing false alarms, and the associated loss in trust in the EMM, outweighs the relative gains in accuracy. This inefficiency particularly impacts low-prevalence settings, where radiologists may waste valuable time reviewing cases that the primary model had already classified correctly (Supplementary Fig. 7). This illustrates that although the overall EMM framework can be applied to broad applications, the agreement levels and thresholds may need use-case-specific definitions depending on the disease and its prevalence level.\n\nIn our analysis of features associated with high EMM agreement levels, we also identified some less intuitive directional relationships. For instance, higher EMM agreement levels in ICH-negative cases were associated with smaller brain volume and reduced rotation and translation from image registration, such as in the MNI152 template space37. These associations may reflect underlying confounding factors. For example, a smaller brain volume may cause a hemorrhage to appear proportionally larger relative to the total brain size, making it more easily detectable by the primary model. Younger age may also be associated with fewer ICH-mimicking features that may confuse the primary model, such as calcifications38. Similarly, higher confidence in images with minimal translation and rotation may suggest that the primary model training dataset is biased toward orientations close to the MNI152 template. This may be due to a known limitation that many CNN models lack rotational equivariance39. Although other confounders may be present and future studies should further investigate how these features directly relate to EMM\u2019s capability to estimate confidence, EMM was still able to estimate confidence and stratify cases accordingly.\n\nVarying the technical parameters of EMM also revealed insight into the best practices for applying EMM to other clinical use cases. Our ablation study revealed that, expectedly, larger datasets, a larger number of sub-models, and larger sub-models generally improve the EMM\u2019s capability to detect errors in the primary model. We observed that EMM, when trained on only 25% of the data, achieved near-optimal performance at disease prevalences of 30 and 15%, indicating EMM\u2019s strong generalizability in data-scarce settings with relatively high prevalence. We also observed that at 5% prevalence, large sub-models trained with 25% of the data or small models trained with 5% of the data achieved optimal performance. This behavior can be explained by the relationship between model complexity and data volume. Specifically, large sub-models trained on the full dataset (with 41% prevalence) likely became too calibrated/overfitted to that specific prevalence distribution, causing suboptimal performance when testing on data with significantly different prevalence (5%)40. Using large sub-model training with 25% of data or using small sub-model training with 5% of data may help the EMM balance the bias-variance tradeoffs by learning meaningful patterns for generalizability, while not overfitting to the training prevalence. The differences observed in optimal dataset size and sub-model size across different prevalence levels can help inform the best technical parameters to start developing an EMM for a different use case, promoting greater adoptability across diseases.\n\nBeyond using EMM to improve case-by-case primary model performance, as shown in this study, another potential application of EMM can be monitoring longitudinal changes in primary model performance. As the EMM agreement levels are tracked over time, perturbations in the expected ranges can be identified over daily, weekly, or monthly periods. For example, any significant drifts in EMM agreement level distribution may signal changes in primary model performance due to shifts in patient demographics, image acquisition parameters, or clinical workflows. In this manner, the EMM approach can provide another dimension to the current radiology statistical process/quality control pipelines for continuous background monitoring41,42, in addition to reporting concordance.\n\nWhile the EMM approach demonstrates several advantages in case-by-case AI monitoring, some limitations persist. Although the EMM does not require labels to perform its monitoring task after deployment, a key constraint is the need for labeled use-case-specific datasets when training the EMM for each clinical application, which could potentially limit broader adoption across diverse clinical institutions with different labeling and computing resources. Similarly, the extent of retraining, recalibration, or additional data required as the primary model, prevalence, and imaging protocol evolve remains an open question, and future work should aim to systematically evaluate the extent of adaptation needed to maintain EMM performance in such scenarios. With the recent maturity of LLMs and self-supervised model training techniques, these data limitations may be largely overcome. For example, labels can now be automatically extracted from existing radiology reports using LLMs11,12,13. Self-supervised training43,44 also enables large foundation model training without manual annotation45,46, and only a small amount of labeled data would be required to further fine-tune the model for each use case. These recent developments enable periodic updates to EMM, allowing it to adapt to changes in patient populations, scanners, and imaging protocols, thereby maintaining consistent and robust performance over time.\n\nIn this study, our ground-truth labels were generated independently by two radiologists without a secondary inter-reader review (one radiologist annotated the ICH types, while the other performed the ICH segmentation). Although both annotators have several years of experience (six and three years, respectively), labeling errors may still occur due to human error. In addition, although the RSNA 2019 dataset prohibits commercial use, it is unclear whether the FDA-cleared primary model was trained on this dataset. Nonetheless, even with the possibility of an overlap in the training data between the primary model and EMM, our results derived from our private testing dataset indicate that the EMM approach maintains strong performance despite this potential limitation.\n\nWhile we explored EMM performance across different primary models, varying amounts of training data, different numbers and sizes of sub-models, and a range of disease prevalences, all evaluations were conducted on a single internal dataset, which may be subject to biases specific to our patient population or our ICH use case. For example, we observed discrepancies in EMM performance in gender, age, and race subgroups (Supplementary Fig. 6). This may be due to dataset bias commonly observed in healthcare AI44, potentially resulting from underrepresentation in the EMM training dataset or a mismatch between the training and testing subgroup distributions. To address these limitations, future work is needed not just to investigate the generalizability of the EMM framework to applications beyond ICH and across institutions with diverse patient populations, scanner types, and imaging protocols, but also to develop methods that can enhance its generalizability in these varied settings. In addition, clinician-centered evaluations are needed to assess how EMM\u2019s case-specific confidence impacts radiologists\u2019 workflow, efficiency, trust in AI, and cognitive load. The alignment between EMM\u2019s confidence and radiologists\u2019 interpretations may vary based on individual traits and levels of experience, underscoring the importance of human-centered assessment47.\n\nAnother limitation is EMM\u2019s susceptibility to similar failure patterns as the primary model being monitored, such as in cases involving small, low-contrast hemorrhages or ICH-mimicking pathologies in this study. Of particular concern are instances where EMM fails simultaneously with the primary model while indicating complete consensus, as this could instill false confidence in clinicians and potentially increase misdiagnosis risk. This risk might be mitigated by training EMM in the future using synthetic datasets48 with artificially generated difficult cases, such as those with less obvious hemorrhages, with ICH-mimicking features, representing a diverse patient population, or with various artifacts. As AI technology rapidly develops, many of the limitations currently facing EMM may be quickly overcome, presenting greater opportunities to not only improve EMM performance but also the resources required to implement the EMM approach itself.\n\nIn conclusion, our EMM framework represents a significant advancement in black-box clinical AI monitoring, enabling case-by-case confidence estimation without requiring access to primary model parameters or intermediate outputs. By leveraging ensemble agreement levels, EMM provides actionable insights, potentially enhancing diagnostic confidence while reducing cognitive burden. As AI continues to integrate into clinical workflows, approaches like EMM that provide transparent confidence measures will be essential for maintaining trust, ensuring quality, and ultimately improving patient outcomes in resource-constrained environments.\nMethods\nPrimary ICH detection AI models\n\nWe evaluated EMM\u2019s monitoring capabilities on two distinct ICH detection AI systems: an FDA-cleared commercial product and an open-source model that secured second place in the RSNA 2019 ICH detection challenge35,49.\n\nThe FDA-cleared primary model is a black-box system with undisclosed training data and architecture that provides binary labels for the presence of ICH and identifies suspicious slices. We monitored this model using EMM trained on the complete (100%, N\u2009=\u200918,370) RSNA 2019 ICH Detection Challenge dataset. While this dataset\u2019s license restricts usage to academic and non-commercial purposes, we do not have access to information regarding whether the FDA-cleared primary model utilized this dataset during its development.\n\nThe open-source RSNA 2019 Challenge second-place model34 employs a 2D ResNext-10150 network for slice-level feature extraction, followed by two levels of Bidirectional LSTM networks for feature summarization and ICH detection. We selected the second-place model rather than the first-place winner because retraining the top model would require extensive time while offering only marginal performance improvement (\u22642.3%) based on the leaderboard. Although the original open-source primary model was trained on the complete RSNA Challenge dataset, we retrained it using only 50% of the data and reserved the remaining 50% for EMM training. This simulates real-world deployment scenarios where the primary model and EMM are trained on different datasets. For both the FDA-cleared and the open-source primary models, preprocessing is already built into the software; therefore, no additional image preprocessing was performed, and the original DICOM was sent as the input.\nEMM training dataset and details\n\nEMM consisted of five independently trained 3D convolutional neural networks (CNNs), comprising two versions with different numbers of trainable parameters: a large version utilizing ResNet51 101 and 152, and DenseNet52 121, 169, and 201; and a small version employing ResNet 18, 34, 50, 101, and 152. These networks were initialized using 2D ImageNet53 pre-trained weights and adapted to 3D via the Inflated 3D (I3D)54 method, which has shown success previously46. EMM sub-models were trained using the open-source RSNA 2019 ICH Detection Challenge35,49 dataset and was evaluated using an independent dataset collected at our institution. We trained the models on different subsets of the RSNA dataset to investigate EMM\u2019s data efficiency across different amounts of training data used, including 18,370 (100%), 9185 (50%), 4592 (25%), and 918 (5%) studies. All subsets had an ICH prevalence of about 41%. EMM training details and parameters are shown in Supplementary Table 1.\nEMM evaluation dataset\n\nWe evaluated the EMM using an independent dataset of 2919 CT studies collected at our institution, with no overlap with the EMM training data. The dataset included 1315 ICH-positive and 1604 ICH-negative cases (45% ICH prevalence), featured a balanced gender distribution (50.1% male and 49.8% female), and spanned a wide age range (0.16\u2013104.58 years; median: 67.13 years; interquartile range: 49.65\u201380.00 years). Since AI model performance is known to vary with disease prevalence55,56, we evaluated both the primary model and EMM performance across different prevalence levels. A recent internal evaluation at our institution covering 8935 studies between July and November 2024 revealed ICH prevalences of 34.77% for in-patient, 9.09% for out-patient, and 6.52% for emergency units, with an overall average prevalence of 16.70%. Based on these observations, we selected three representative prevalence levels for evaluation: 30, 15, and 5%. This study was approved by the Stanford Institutional Review Board (IRB-58903) with a waiver of informed consent due to the use of retrospective data.\nEMM training\n\nTo prepare input data for the EMM, we preprocessed all non-contrast axial head CT DICOM images using the Medical Open Network for AI (MONAI) toolkit57. The preprocessing pipeline consisted of several standardization steps: reorienting images to the \u201cleft-posterior-superior\u201d (LPS) coordinate system, normalizing the in-plane resolution to 0.45\u2009mm, and resizing (either cropping or padding, depending on the matrix size) the in-plane matrix dimensions to 512\u2009\u00d7\u2009512 pixels using PyTorch\u2019s adaptive average pool method, while preserving the original slice resolution. During training, we employed random cropping in the slice dimension, selecting a contiguous block of 30 slices. For testing, we used a sliding window of 30 slices and averaged the ICH SoftMax probabilities across overlapping windows to generate the final prediction.\nManually annotated sub-dataset for Shapley analysis\n\nTo comprehensively analyze features that drive high EMM agreement, we manually annotated a smaller dataset (N\u2009=\u2009281), including ICH segmentation, volume measurements, and identification of mimicking imaging features. This curated dataset comprised 210 ICH-positive and 71 ICH-negative subjects and their associated studies. The ICH-positive cases span seven distinct ICH subtypes: subdural (SDH, N\u2009=\u200935), subarachnoid (SAH, N\u2009=\u200950), epidural (EDH, N\u2009=\u200915), intraparenchymal (IPH, N\u2009=\u200919), intraventricular (IVH, N\u2009=\u20092), diffuse axonal injury (DAI, N\u2009=\u20091), and multi-compartmental hemorrhages (Multi-H, N\u2009=\u200988). Among the 71 ICH-negative cases, 43 cases were specifically selected to include features that mimic hemorrhages (e.g., hyperdensity such as calcification or tumor), while 28 were from normal subjects. A neuroradiology fellow with 6 years of experience reviewed and validated all clinical labels to ensure accurate ground truth for our analysis.\nComprehensive list of features for Shapley analysis\n\nIn Shapley analysis, we prepared a comprehensive list of features including pathology-related metrics (ICH volume and type), patient characteristics (brain volume, age, and gender), positioning parameters (rotation and translation), image acquisition parameters (pixel spacing, slice thickness, kVp, X-ray tube current, and CT scanner manufacturer), and image reconstruction parameters (reconstruction convolution kernel and filter type). It is worth noting that these features are not used by EMM to make predictions, but rather represent real-world factors that may correlate with the EMM agreement levels.\nExplaining features contributing to high EMM agreement using Shapley analysis\n\nTo elucidate the features contributing to the high level of agreement between EMM sub-models and the primary model, we conducted Shapley analysis36 using the Python \u201cshap\u201d package (v0.46.0). This analysis employed an XGBoost58 (v2.1.1) classifier to learn the relationship between feature values and EMM agreement and to evaluate the importance of each feature leading to high EMM agreement, quantified by the probability ranges between 0 and 1. Higher Shapley values indicate features important for 100% EMM agreement.\nICH volume estimation for Shapley analysis\n\nTo evaluate whether ICH volume influences EMM monitoring performance, we implemented a systematic protocol for ICH volume estimation. First, we employed Viola-UNet59, the winning model from the Instance 2022 ICH Segmentation Challenge60,61, to generate initial ICH segmentations. A radiology resident with 3 years of experience reviewed these segmentations and marked any errors directly on the images. A trained researcher then manually corrected the marked discrepancies using 3D Slicer software (version 5.6.2) to ensure accurate hemorrhage delineation. Finally, we calculated ICH volumes using the corrected ICH masks and image resolution data from the DICOM headers.\nEstimating patient brain volume and orientation information for Shapley analysis\n\nSince hemorrhage detection can be challenging in brains of different sizes or certain brain orientations, we analyzed brain volume and orientation as potential factors affecting EMM performance, alongside the previously mentioned features. Using the FMRIB Software Library62 (FSL 6.0.7.13), we developed an automated pipeline following an established protocol63 to extract brain masks and estimate brain volumes. We then employed FSL FLIRT (FMRIB\u2019s Linear Image Registration Tool) to perform 9-degree-of-freedom brain registration, aligning each image to the MNI 2019b non-symmetrical T1 brain template37. The resulting rotation, translation, and scaling parameters were incorporated into our Shapley analysis as quantitative measures of brain orientation.\nAnalysis of the tradeoff between false-alarm rate and the relative accuracy improvement\n\nWhen the decreased confidence group in Fig. 3 is further reviewed by radiologists, some cases may actually be found to be labeled correctly by the primary model; we consider these cases to be false alarms. The false-alarm rate is defined as the percentage of unnecessary reviews of correctly labeled cases. After further reviewing the cases in the decreased confidence group, we assumed that the radiologists would always correctly label the cases, improving overall accuracy. While this assumption may not always hold, especially in complex borderline cases, this analysis demonstrates the maximum accuracy improvement that can be gained from using the EMM framework. We define relative improvement in accuracy as the percentage increase in accuracy after reviewing the decreased confidence group compared to the baseline accuracy of the primary model, i.e.,\nStatistical analysis\n\nTo assess the reliability of both primary models and EMM\u2019s performance metrics, we calculated 95% confidence intervals (CIs) using bootstrapping. We conducted 1000 random draws across studies with replacement from the set of ground-truth labels and corresponding model predictions. To create an evaluation dataset at target prevalence levels (30, 15, and 5%) different from the original distribution (45%), we down-sampled ICH-positive and resampled ICH-negative cases. For example, to create datasets with a controlled 30% prevalence of ICH-positive cases, we performed random sampling with replacement from our original dataset. Specifically, we randomly selected 0.3\u2009\u00d7\u2009Nn ICH-positive cases and Nn ICH-negative cases (where Nn represents the total number of ICH-negative cases in the original dataset). After each draw, we computed key performance metrics such as sensitivity, positive predictive value (PPV), specificity, and negative predictive value (NPV). We then determined the 95% confidence intervals by identifying the 2.5th and 97.5th percentiles of these metrics across all bootstrap iterations.\n\nTo test the significance of differences in metrics between different groups, percentile bootstrapping paired-samples test was also applied to estimate the p value, with the null hypothesis that there is no difference between the two paired groups. This test was performed using a customized Python script mirroring computations in R boot.paired.per function (https://rdrr.io/cran/wBoot/man/boot.paired.per.html). For the sex, age, and race subgroup analysis, we performed a non-parametric bootstrap ANOVA test for ED-SPAUC and ED-SNAUC. Following bootstrapping resampling and variance comparison, we computed an observed F-statistic from bootstrapped samples and compared it to a null distribution generated by permuting group labels64.\nData availability\n\nThe EMM training dataset is based on the RSNA 2019 ICH detection challenge, and it can be found at https://www.rsna.org/rsnai/ai-image-challenge/rsna-intracranial-hemorrhage-detection-challenge-2019. Internal validation data are under internal review and will publish through Stanford University.\nCode availability\n\nEMM code and model weights are available publicly on GitHub (https://github.com/stanfordaide/ICH_EMM).\nReferences\n\n    Joshi, G. et al. FDA-approved artificial intelligence and machine learning (AI/ML)-enabled medical devices: an updated landscape. Electronics 13, 498 (2024).\n\n    Article\n     \n    Google Scholar\n     \n\n    Challen, R. et al. Artificial intelligence, bias and clinical safety. BMJ Qual. Saf. 28, 231\u2013237 (2019).\n\n    Article\n     \n    PubMed\n     \n    PubMed Central\n     \n    Google Scholar\n     \n\n    Khera, R., Simon, M. A. & Ross, J. S. Automation bias and assistive AI: risk of harm from AI-driven clinical decision support. JAMA 330, 2255\u20132257 (2023).\n\n    Article\n     \n    PubMed\n     \n    Google Scholar\n     \n\n    Del Gaizo, A. J., Osborne, T. F., Shahoumian, T. & Sherrier, R. Deep learning to detect intracranial hemorrhage in a national teleradiology program and the impact on interpretation time. Radiol. Artif. Intell. 6, e240067 (2024).\n\n    Health, C. for D. and R. Blog: a lifecycle management approach toward delivering safe, effective AI-enabled health Care. FDA (2025).\n\n    Allen, B. et al. Evaluation and real-world performance monitoring of artificial intelligence models in clinical practice: try It, buy It, check It. J. Am. Coll. Radiol. 18, 1489\u20131496 (2021).\n\n    Article\n     \n    PubMed\n     \n    Google Scholar\n     \n\n    Chow, J., Lee, R. & Wu, H. How do radiologists currently monitor AI in radiology and what challenges do they face? An interview study and qualitative analysis. J. Digit. Imaging Inform. Med. https://doi.org/10.1007/s10278-025-01493-8 (2025).\n\n    Larson, D. B. et al. Assessing completeness of clinical histories accompanying imaging orders using adapted open-source and closed-source large language models. Radiology 314, e241051 (2025).\n\n    Article\n     \n    PubMed\n     \n    Google Scholar\n     \n\n    Van Veen, D. et al. Adapted large language models can outperform medical experts in clinical text summarization. Nat. Med. 30, 1134\u20131142 (2024).\n\n    Article\n     \n    PubMed\n     \n    PubMed Central\n     \n    Google Scholar\n     \n\n    Li, L. et al. A scoping review of using large language models (LLMs) to investigate electronic health records (EHRs). Preprint at https://doi.org/10.48550/arXiv.2405.03066 (2024).\n\n    Le Guellec, B. et al. Performance of an open-source large language model in extracting information from free-text radiology reports. Radiol. Artif. Intell. 6, e230364 (2024).\n\n    Article\n     \n    PubMed\n     \n    PubMed Central\n     \n    Google Scholar\n     \n\n    Reichenpfader, D., M\u00fcller, H. & Denecke, K. Large language model-based information extraction from free-text radiology reports: a scoping review protocol. BMJ Open 13, e076865 (2023).\n\n    Article\n     \n    PubMed\n     \n    PubMed Central\n     \n    Google Scholar\n     \n\n    Reichenpfader, D., M\u00fcller, H. & Denecke, K. A scoping review of large language model based approaches for information extraction from radiology reports. npj Digit. Med. 7, 222 (2024).\n\n    Article\n     \n    PubMed\n     \n    PubMed Central\n     \n    Google Scholar\n     \n\n    Lambert, B., Forbes, F., Doyle, S., Dehaene, H. & Dojat, M. Trustworthy clinical AI solutions: a unified review of uncertainty quantification in deep learning models for medical image analysis. Artif. Intell. Med. 150, 102830 (2024).\n\n    Article\n     \n    PubMed\n     \n    Google Scholar\n     \n\n    Gawlikowski, J. et al. A survey of uncertainty in deep neural networks. Artif. Intell. Rev. 56, 1513\u20131589 (2023).\n\n    Article\n     \n    Google Scholar\n     \n\n    Kiyasseh, D., Cohen, A., Jiang, C. & Altieri, N. A framework for evaluating clinical artificial intelligence systems without ground-truth annotations. Nat. Commun. 15, 1808 (2024).\n\n    Article\n     \n    PubMed\n     \n    PubMed Central\n     \n    CAS\n     \n    Google Scholar\n     \n\n    Ramalho, T. & Miranda, M. In International Workshop on Engineering Dependable and Secure Machine Learning Systems 84-96 (2020).\n\n    Raghu, M. et al. Direct uncertainty prediction for medical second opinions. In Proc. 36th International Conference on Machine Learning 5281\u20135290 (2019).\n\n    Malinin, A. & Gales, M. in Advances in Neural Information Processing Systems 31 (2018).\n\n    Kull, M. et al. in Advances in Neural Information Processing Systems Vol. 32 (Curran Associates, Inc., 2019).\n\n    Guo, C., Pleiss, G., Sun, Y. & Weinberger, K. Q. On calibration of modern neural networks. In Proc. 34th International Conference on Machine Learning 1321\u20131330 (2017).\n\n    Kumar, A., Liang, P. S. & Ma, T. Verified uncertainty calibration. In Advances in Neural Information Processing Systems (2019).\n\n    Louizos, C. & Welling, M. Multiplicative normalizing flows for variational Bayesian neural networks. In Proc. 34th International Conference on Machine Learning 2218\u20132227 (2017).\n\n    Ritter, H., Botev, A. & Barber, D. A scalable Laplace approximation for neural networks. In Proc. 6th International Conference on Learning Representations (ICLR) 6 (2018).\n\n    Welling, M. & Teh, Y. W. Bayesian learning via stochastic gradient langevin dynamics. In Proc. 28th International Conference on Machine Learning 681\u2013688 (2011).\n\n    Graves, A. Practical variational inference for neural networks. In Advances in Neural Information Processing Systems 24 (2011).\n\n    Gal, Y. & Ghahramani, Z. Dropout as a Bayesian approximation: representing model uncertainty in deep learning. In Proc. 33rd International Conference on Machine Learning 1050\u20131059 (2016).\n\n    Lemay, A. et al. Improving the repeatability of deep learning models with Monte Carlo dropout. npj Digit. Med. 5, 1\u201311 (2022).\n\n    Article\n     \n    Google Scholar\n     \n\n    Egele, R. et al. AutoDEUQ: automated deep Ensemble with uncertainty quantification. In Proc. 26th International Conference on Pattern Recognition (ICPR) 1908\u20131914 (2022).\n\n    Mehrtash, A., Wells, W. M., Tempany, C. M., Abolmaesumi, P. & Kapur, T. Confidence calibration and predictive uncertainty estimation for deep medical image segmentation. IEEE Trans. Med. Imaging 39, 3868\u20133878 (2020).\n\n    Article\n     \n    PubMed\n     \n    PubMed Central\n     \n    Google Scholar\n     \n\n    Wenzel, F., Snoek, J., Tran, D. & Jenatton, R. Hyperparameter Ensembles for robustness and uncertainty quantification. In Advances in Neural Information Processing Systems 6514\u20136527 (2020).\n\n    Lakshminarayanan, B., Pritzel, A. & Blundell, C. Simple and scalable predictive uncertainty estimation using deep Ensembles. In Advances in Neural Information Processing Systems 30 (2017).\n\n    Kwon, Y., Won, J.-H., Kim, B. J. & Paik, M. C. Uncertainty quantification using Bayesian neural networks in classification: application to biomedical image segmentation. Computat. Stat. Data Anal. 142, 106816 (2020).\n\n    Article\n     \n    Google Scholar\n     \n\n    Hanley, D. RSNA intracranial hemorrhage detection. Second place winner (2024).\n\n    Flanders, A. E. et al. Construction of a machine learning dataset through collaboration: the RSNA 2019 brain CT hemorrhage challenge. Radiol. Artif. Intell. 2, e190211 (2020).\n\n    Lundberg, S. M. & Lee, S. I. A unified approach to interpreting model predictions. In Advances in Neural Information Processing Systems 30 (2017).\n\n    Fonov, V., Evans, A., McKinstry, R., Almli, C. & Collins, D. Unbiased nonlinear average age-appropriate brain templates from birth to adulthood. Neuroimage 47, S102 (2009).\n\n    Article\n     \n    Google Scholar\n     \n\n    Saade, C. et al. Intracranial calcifications on CT: an updated review. J. Radiol. Case Rep. 13, 1\u201318 (2019).\n\n    Article\n     \n    PubMed\n     \n    PubMed Central\n     \n    Google Scholar\n     \n\n    Winkels, M. & Cohen, T. S. Pulmonary nodule detection in CT scans with equivariant CNNs. Med. Image Anal. 55, 15\u201326 (2019).\n\n    Article\n     \n    PubMed\n     \n    Google Scholar\n     \n\n    Mutasa, S., Sun, S. & Ha, R. Understanding artificial intelligence based radiology studies: What is overfitting?. Clin. Imaging 65, 96\u201399 (2020).\n\n    Article\n     \n    PubMed\n     \n    PubMed Central\n     \n    Google Scholar\n     \n\n    Feng, J. et al. Clinical artificial intelligence quality improvement: towards continual monitoring and updating of AI algorithms in healthcare. npj Digit. Med. 5, 1\u20139 (2022).\n\n    Article\n     \n    Google Scholar\n     \n\n    Larson, D. B. A vision for global CT radiation dose optimization. J. Am. Coll. Radiol. 21, 1311\u20131317 (2024).\n\n    Article\n     \n    PubMed\n     \n    Google Scholar\n     \n\n    Huang, S.-C. et al. Multimodal foundation models for medical imaging - a systematic review and implementation guidelines. Preprint at https://doi.org/10.1101/2024.10.23.24316003 (2024).\n\n    Huang, S.-C. et al. Self-supervised learning for medical image classification: a systematic review and implementation guidelines. npj Digit. Med. 6, 1\u201316 (2023).\n\n    Article\n     \n    CAS\n     \n    Google Scholar\n     \n\n    Chen, Z. et al. A vision-language foundation model to enhance efficiency of chest X-ray interpretation. Preprint at https://doi.org/10.48550/arXiv.2401.12208 (2024).\n\n    Blankemeier, L. et al. Merlin: a vision language foundation model for 3D computed tomography. Preprint at https://doi.org/10.48550/arXiv.2406.06512 (2024).\n\n    K\u00fcper, A. & Kr\u00e4mer, N. Psychological traits and appropriate reliance: factors shaping trust in AI. Int. J. Hum.\u2013Comput. Interact. 41, 4115\u20134131 (2025).\n\n    Google Scholar\n     \n\n    Bluethgen, C. et al. A vision\u2013language foundation model for the generation of realistic chest X-ray images. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-024-01246-y (2024).\n\n    RSNA intracranial hemorrhage detection callenge. https://www.rsna.org/rsnai/ai-image-challenge/rsna-intracranial-hemorrhage-detection-challenge-2019 (2019).\n\n    Xie, S., Girshick, R., Dollar, P., Tu, Z. & He, K. Aggregated residual transformations for deep neural networks. In 2017 IEEE Conference on Computer Vision and Pattern Recognition (CVPR) 5987\u20135995 (2017).\n\n    He, K., Zhang, X., Ren, S. & Sun, J. Deep residual learning for image recognition. In Proc. of the IEEE conference on computer vision and pattern recognition 770-778 (2016).\n\n    Huang, G., Liu, Z., Van Der Maaten, L. & Weinberger, K. Q. Densely connected convolutional networks. In 2017 IEEE Conference on Computer Vision and Pattern Recognition (CVPR) 2261\u20132269 (2017).\n\n    Russakovsky, O. et al. ImageNet large scale visual recognition challenge. Int. J. Comput. Vis. 115, 211-252 (2016).\n\n    Carreira, J. & Zisserman, A. Quo Vadis, action recognition? A new model and the kinetics dataset. In 2017 IEEE Conference on Computer Vision and Pattern Recognition (CVPR) 4724\u20134733 (2017).\n\n    Godau, P. et al. Navigating prevalence shifts in image analysis algorithm deployment. Med. Image Anal. 102, 103504 (2025).\n\n    Article\n     \n    PubMed\n     \n    Google Scholar\n     \n\n    Park, S. H. & Han, K. Methodologic guide for evaluating clinical performance and effect of artificial intelligence technology for medical diagnosis and prediction. Radiology 286, 800\u2013809 (2018).\n\n    Article\n     \n    PubMed\n     \n    Google Scholar\n     \n\n    Cardoso, M. J. et al. MONAI: an open-source framework for deep learning in healthcare. Preprint at https://doi.org/10.48550/ARXIV.2211.02701 (2022).\n\n    Chen, T. & Guestrin, C. XGBoost: a scalable tree boosting system. In Proc. 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining 785\u2013794 (2016).\n\n    Liu, Q. et al. Voxels intersecting along orthogonal levels attention U-net for intracerebral haemorrhage segmentation in head CT. In IEEE 20th International Symposium on Biomedical Imaging (ISBI) 1\u20135 (2023).\n\n    Li, X. et al. Hematoma expansion context guided intracranial hemorrhage segmentation and uncertainty estimation. IEEE J. Biomed. Health Inform. 26, 1140\u20131151 (2022).\n\n    Article\n     \n    PubMed\n     \n    Google Scholar\n     \n\n    Li, X. et al. The state-of-the-art 3D anisotropic intracranial hemorrhage segmentation on non-contrast head CT: the INSTANCE challenge. Preprint at https://doi.org/10.48550/arXiv.2301.03281 (2023).\n\n    Smith, S. M. et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 23, S208\u2013S219 (2004).\n\n    Article\n     \n    PubMed\n     \n    Google Scholar\n     \n\n    Muschelli, J. et al. Validated automatic brain extraction of head CT images. Neuroimage 114, 379\u2013385 (2015).\n\n    Article\n     \n    PubMed\n     \n    Google Scholar\n     \n\n    Maris, E. & Oostenveld, R. Nonparametric statistical testing of EEG- and MEG-data. J. Neurosci. Methods 164, 177\u2013190 (2007).\n\n    Article\n     \n    PubMed\n     \n    Google Scholar\n      \n\nDownload references\nAcknowledgements\n\nStanford Department of Radiology; Stanford 3D and Quantitative Imaging Laboratory (3DQ Lab).\nAuthor information\nAuthor notes\n\n    These co-senior authors contributed equally: Akshay S. Chaudhari, David B. Larson.\n\nAuthors and Affiliations\n\n    Department of Radiology, School of Medicine, Stanford University, Stanford, CA, 94304, USA\n\n    Zhongnan Fang, Andrew Johnston, Lina Y. Cheuy, Hye Sun Na, Magdalini Paschali, Camila Gonzalez, Bonnie A. Armstrong, Arogya Koirala, Derrick Laurel, Andrew Walker Campion, Michael Iv, Akshay S. Chaudhari & David B. Larson\n\n    AI Development and Evaluation Laboratory (AIDE), School of Medicine, Stanford University, Stanford, CA, 94304, USA\n\n    Zhongnan Fang, Andrew Johnston, Lina Y. Cheuy, Hye Sun Na, Magdalini Paschali, Camila Gonzalez, Bonnie A. Armstrong, Arogya Koirala, Akshay S. Chaudhari & David B. Larson\n\n    3D and Quantitative Imaging Laboratory (3DQ), School of Medicine, Stanford University, Stanford, CA, 94304, USA\n\n    Derrick Laurel\n\n    Department of Biomedical Data Science, School of Medicine, Stanford University, Stanford, CA, 94304, USA\n\n    Akshay S. Chaudhari\n\nContributions\n\nManuscript drafting and manuscript revision for important intellectual content, all authors; Study concepts and design: Z.F., A.S.C., and D.B.L.; Data/statistical analysis: Z.F.; Data collection: D.L., A.W.C., and M.I.; Data cleaning and annotation: Z.F., A.J., H.S.N., M.P., C.G., A.K., D.L., and A.W.C.; Literature research: Z.F., L.Y.C., A.S.C., M.P., and C.G.\nCorresponding author\n\nCorrespondence to Zhongnan Fang.\nEthics declarations\nCompeting interests\n\nZ.F. Stock option holder of LVIS Corp. A.J. No relevant relationships. L.Y.C. No relevant relationships. H.S.N. No relevant relationships. M.P. No relevant relationships. C.G. No relevant relationships. B.A.A. No relevant relationships. A.K. No relevant relationships. D.L. No relevant relationships. A.W.C. No relevant relationships. M.I. No relevant relationships. D.B.L. Member of the Board of Chancellors of the American College of Radiology and Board of Trustees of the American Board of Radiology, shareholder in Bunkerhill Health; receives research funding from the Gordon and Betty Moore Foundation. A.S.C. receives research support from NIH grants R01 HL167974, R01HL169345, R01 AR077604, R01 EB002524, R01 AR079431, P41 EB027060; ARPA-H grants AY2AX000045 and 1AYSAX0000024-01; and NIH contracts 75N92020C00008 and 75N92020C00021.Unrelated to this work, A.S.C. receives research support from GE Healthcare, Philips, Microsoft, Amazon, Google, NVIDIA, Stability; has provided consulting services to Patient Square Capital, Chondrometrics GmbH, and Elucid Bioimaging; is co-founder of Cognita; has equity interest in Cognita, Subtle Medical, LVIS Corp, and Brain Key.\nAdditional information\n\nPublisher\u2019s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.\nSupplementary information\nEMM_revision1_supp\nRights and permissions\n\nOpen Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article\u2019s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article\u2019s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.\n\nReprints and permissions\n"
    }
  ],
  "rubrics": [
    "The response should not contain hallucinated citations.",
    "The response should provide at least one specific source for further reading. For example, it should suggest a specific paper or article and not just give a general suggestion.",
    "The response should summarise the 3 papers independently from one another. For example, it should not combine them into one summarisation, they should each receive a separate summary and title.",
    "The response should make use of Harvard referencing style in the references list, when possible.",
    "The response should be presented in the following numbered format: 1) Direct answer 2) Justification and explanation 3) References 4) Further reading.",
    "The response should not include any opinionated statements. For example, it should not include statements about the quality or importance of the research discussed.",
    "The response should provide an additional source on artificial intelligence that is very recent. for example, it should provide a source from 2024 or 2025.",
    "The response should state that the JAMA Summit: AI concluded that AI will disrupt every aspect of health care and that  developers, providers and patients should be aligned on how to address these disruptions.",
    "The response should state that King, et. al. discusses the advantages and disadvantages of citizen scientists using artificial intelligence tools.",
    "The response should include an example from King, et. al. of AI being used by the public in the realm of science. For example, the response could mention the technology-enabled \u201cOur Voice\u201d Global Citizen Science Research Initiative.",
    "The response should state that Fang, et. al. describes the Ensembled Monitoring Model, a framework designed to streamline the use of commercial AI tools in clinical settings.",
    "The response should details of the performance of EMM from the paper Fang, et. al. For example, the response could mention that there were differences in performance of the EMM framework for subgroups based on age, sex, and race."
  ],
  "metadata": {
    "task_id": "7f7e0e7b-506c-4d28-91e3-93119513960d",
    "context_id": "23784939-444b-4440-bf6d-c2e080a548b3",
    "context_category": "Domain Knowledge Reasoning",
    "sub_category": "Healthcare"
  }
}